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My PhD thesis is written in a cumulative format and consists of a general introduction 
about polyomaviruses, its related diseases and polyomavirus-specific immune response. The 
cumulative part includes six publications and one manuscript: The first two publications give 
an overview about polyomavirus related problems in transplant recipients and management of 
polyomavirus diseases. Three publications elucidate the polyomavirus-specific immune 
response to different viral proteins. The sixth publication is a case report about a patient 
suffering from polyomavirus-associated nephropathy. The manuscript is about 
cytomegalovirus, a latent virus also causing problems in the transplant setting like 
polyomaviruses. Finally, two chapters about current projects summarize the experiments done 
until today. 
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1. INTRODUCTION 
 
1.1 GENERAL INTRODUCTION TO HUMAN POLYOMAVIRUSES 
Polyomaviruses are able to infect, to replicate in and to induce different diseases in natural 
and accidental hosts. The following chapters focus on the two human polyomaviruses type 1 
and type 2 which were first isolated in 1971 and designated BK virus (BKV) and JC virus 
(JCV) after the initials of the respective patients (Gardner et al. 1971; Padgett et al. 1971). 
Other polyomaviruses such as SV40, KI and WU, are also known to infect humans. 
Human exposure to polyomavirus SV40 occurred through contaminated poliovirus 
vaccines in the United States between 1955 and 1963. Because of the carcinogenicity of SV40 
in infected rodents, many studies have been performed to determine if there is an association 
between SV40 infection and cancer in human (Paracchini et al. 2006). SV40 is the best 
investigated polyomavirus and most findings about polyomavirus properties are due to 
extensive SV40 research. 
Recently the DNA of two new polyomaviruses KI and WU could be isolated by 
polymerase chain reaction (PCR) from respiratory tract samples mainly from children less 
than 3 years of age (Allander et al. 2007; Gaynor et al. 2007). These two viruses share 
strikingly similar properties as both do not code for agnoprotein and both are lacking the large 
turmor (LT) /antigen host range domain at the carboxyl terminus, responsible for viral 
assembly (Chapter 1.1.2.1) (Pipas 1992). KI and WU have an amino acid sequence 
homology of 70% for LT-antigen and 65% for viral capsid protein 1 (VP1). In contrast, there 
is only a low level homology to BKV and JCV (LT-antigen: 49% and 48%, and VP1: 28% 
and 27%, respectively). Whether polyomaviruses KI and WU are able to induce a disease and 
if they also have transforming properties needs further investigation. 
The genomic organization of polyomavirus BK, JC, SV40, KI, and WU is conserved 
between these viruses. 
 
 
1.1.1 Polyomavirus Genomic Organization 
BKV and JCV are non-encapsulated, circular double-stranded DNA viruses of 
approximately 5200 base pairs and are approximately 40-45 nm in diameter. The 
polyomavirus genome has a relatively simple architecture and can be divided into three parts 
according to their functions: 1. Non-coding control region (NCCR), 2. Early genes (coding 
for small and large tumor-antigen), and 3. Late genes (coding for viral capsid proteins 1-3 and 
agnoprotein) (Figure 1.1 and Table 1.1). 
The NCCR is located between the early and late coding regions and contains the origin of 
DNA replication (ori), the TATA box, LT-antigen binding sites, cellular transcription factor-
binding sites, and promoter and enhancer for transcription of early and late genes (Cole et al. 
2001; Moens et al. 2001). The BKV and JCV NCCR may undergo DNA rearrangement in 
vitro and in vivo, and is associated with BKV nephropathy and PML (Sundsfjord et al. 1990). 
The early region is the first part of the genome which is transcribed and translated during 
the viral life cycle. Small tumor (sT) and LT-antigen are produced by alternative splicing of a 
common precursor messenger RNA (mRNA) (Howley et al. 1975; Moens et al. 2001).  
The late region is transcribed and translated after the early region and the precursor mRNA 
is translated to the three capsid proteins VP1-3 and agnoprotein by alternative splicing 
(Kamen et al. 1980; Moens et al. 2001). 
 
 
 
 INTRODUCTION 
_____________________________________________________________________________  
_____________________________________________________________________  
- 3 - 
 
 
Figure 1.1: Polyomavirus BK genome. The NCCR contains sequence blocks (P, Q, R, S) which serve 
as regulatory regions, or enhancer elements. The primary transcript from the early region is 
alternatively spliced in two mRNAs encoding for small and large tumor-antigens. VP1-3 and 
agnoprotein are the gene products from the late region. 
adapted from (Moens et al. 1995; Slavov 2006) 
 
 
Table 1.1: Polyomaviruses BK and JC genomes. 
  Number of bp1 Homology2 
  BKV3 JCV4 BKV-JCV 
Genome (bp)  5153 5130 74% 
large T-antigen 2088 2067 78% Early Coding Region 
small T-antigen 519 519 78% 
     
VP1 1089 1065 75% Late Coding Region 
VP2 1056 1035 81% 
 VP3 699 678 80% 
 Agnoprotein 201 216 72% 
1bp: base pairs, 2Clustal W pairwise alignment, 3BKV-Dunlop strain (NC001538), 4JCV-Mad1 strain 
(NC001699). 
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1.1.2 Polyomavirus Proteins 
BKV and JCV proteins share high amino acid sequence homology (Table 1.2). Each of the 
proteins are expressed at different time points during the virus life cycle and have different 
functionalities important for polyomavirus propagation. 
 
Table 1.2: Polyomaviruses BK and JC proteins. 
Proteins Molecular 
Weight 
(kDa) 
Number of 
Amino Acids 
Sequence 
Homology1 
NCBI 
Accession 
Number 
  BKV JCV BKV-JCV BKV JCV 
Early Proteins       
Large T-antigen 79 695 688 83% P03071 AAA82102
Small T-antigen 20 172 172 78% P03082 AAA82103
       
Late Proteins       
VP1 40 362 354 78% P03088 AAA82101
VP2 37 351 344 79% P03094 AAA82099
VP3 26 232 225 75% P03094 AAA82100
Agnoprotein 8 66 71 59% P03085 AAA82098
1 Clustal W pairwise alignment 
 
 
1.1.2.1 Early Proteins Small and Large T-Antigen and Their Role in Cell 
Transformation and Autoimmunity 
The early protein sT-antigen binds to protein phosphatase 2A (PP2A), a host cell enzyme, 
leading to simultaneous activation of several pathways promoting cell proliferation. PP2A, 
the only confirmed cellular target of sT-antigen, is critical for cell homeostasis and essential 
for cell survival, cell cycle regulation, DNA damage response and embryonic development 
(Janssens et al. 2001; Sontag 2001). Mutation or lower expression levels of PP2A have been 
found in certain cancers. The absence of sT-antigen does not impair viral replication, but sT-
antigen mutants are unable to drive cell proliferation and fail to transform host cells (Moens et 
al. 2001; Skoczylas et al. 2004; Ahuja et al. 2005; White et al. 2005). 
Interest in the transforming ability of polyomaviruses has been triggered by the detection 
of SV40 DNA sequences in some human tumors and has revealed cell transforming properties 
of LT-antigen. The binding of LT-antigen to the heat shock chaperone (hsc70), the 
retinoblastoma family (Rb-family) of tumor suppressors, and to the tumor suppressor p53, 
contribute to transformation (Ali et al. 2001; Saenz-Robles et al. 2001; Sullivan et al. 2002; 
Garcea et al. 2003).  
The structure of the LT-antigen is shown in Figure 1.2. Analysis of this protein revealed 
different domains and functions during polyomavirus life cycle (Chapter 1.2.1). Firstly, LT-
antigen serves as a DNA helicase and promotes the assembly and function of host cell 
proteins. Secondly, it drives the host cell into S-phase by binding and inactivating the 
retinoblastoma susceptibility protein (Rb) family (Dyson et al. 1989; Ewen et al. 1989; 
Hannon et al. 1993; Harris et al. 1996; Caracciolo et al. 2006). Disruption of the Rb-E2F 
complex by LT-antigen leads to an increase of E2F activity, a transcription factor facilitating 
the S-phase progression of the host cell and thus leads to inappropriate cell proliferation 
(DeCaprio et al. 1988; Dyson et al. 1990; Harris et al. 1996; Krynska et al. 1997). The Rb 
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motif LXCXE is required to induce high-density cell growths and release of E2F from Rb 
(Zalvide et al. 1995). E2F release from Rb is also mediated by the J-domain containing the 
HPDKGG motif which recruits the heat shock protein 70 to the Rb-E2F complex where the 
action of the Hsp70-mediated ATP hydrolysis liberates E2F (Campbell et al. 1997; Sullivan et 
al. 2002). The J-domain is not only responsible for cell transformation but is also required for 
viral DNA replication and virion assembly (Peden et al. 1992; Spence et al. 1994). 
 
 
 
Figure 1.2: A) BKV LT-antigen and B) BKV sT-antigen protein structure. J-domain, LXCXE-domain 
and ATPase-p53-domain are able to bind to host cell proteins, NLS: nuclear localization signal 
necessary for the nuclear transport, ZnF: zinc finger region modulates DNA-binding specificity of LT-
antigen, HR: host range domain is required for viral assembly. N-terminal region is identical for LT- 
and sT-antigen. The C-terminal region of sT-antigen contains a stretch of cystein residues. 
adpted from (Pipas 1992; Caracciolo et al. 2006) 
 
 
A third target of LT-antigen is the tumor suppressor protein p53, the main mediator of the 
checkpoint in the cell cycle and initiator of programmed cell death. LT-antigen binds with its 
ATPase-p53 binding domain and inactivates p53, thus preventing inhibition of the cell cycle 
and apoptosis (Bollag et al. 1989; Krynska et al. 1997). The zinc finger (ZnF) region is 
located between the ori DNA binding and ATPase domains and may play a role in 
oligomerization of the protein (Loeber et al. 1989). Additionally it functions mainly in the 
replication of viral DNA and modulates the DNA-bindings specificity of LT-antigen (Pipas 
1992; Nemethova et al. 2004). The host range (HR) domain is located at the C-terminus of 
LT-antigen and is required late in viral productive infection and viral assembly (Pipas 1985; 
Khalili et al. 1988; Stacy et al. 1989). The nuclear localization signal (NLS) is the minimal 
signal sufficient for the nuclear transport of LT-antigen (Zanta et al. 1999). 
In vitro studies have shown the ability of BKV sT- and LT-antigen to induce mutations in 
rodent and human cells (Trabanelli et al. 1998). It could also be shown that LT-antigen not 
only induce mutations in rodent cells but may also transform these cells into a neoplastic 
phenotype (Imperiale 2000; Imperiale 2001; Tognon et al. 2003). These rodent cells 
expressed LT-antigen in their nucleus and the viral DNA was integrated into the cell genome. 
Evidence of a possible role for BKV in human cancer has been supported by the detection 
of BKV-DNA in a range of human tumors such as brain tumors, neuroblastoma, bone tumors, 
insulinomas, Hodgkin's diseases, Kaposi's sarcoma, urinary tract tumors and genital tumors 
(Tognon et al. 2003). Clearly, it needs more investigation to prove that BKV infection is a 
risk factor for the development and/or progression of BKV-associated human tumors as viral 
DNA detection alone is not evidence enough. 
Cysteine motif:
CX5CX7CXCX2CX21CXCX2CX3WFG
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LT-antigen was also linked to the production of autoimmune T- and B-cells directed 
against nucleosomes, particularly to double stranded DNA (dsDNA) and histones. Anti-
dsDNA antibody is a marker for systemic lupus erythematosus (SLE), a disease with a wide 
variety of unrelated manifestations. Several steps are necessary to break the self-tolerance and 
to develop dsDNA-specific B-cells for autoimmunity progression. Different pathways may 
lead to autoimmunity: 1. Autosensitization by release of true autoantigens due to tissue injury, 
2. B- and T-cell activation by cross-reactive viral peptides (mimicry), 3. B- and T-cell 
activation due to presentation of a self-ligand complexed with a non-self molecule, and 4. T-
cell activation due to non-specific bystander activation of autoreactive T-cells (Van Ghelue et 
al. 2003). Here only the last two points will be addressed to the role of LT-antigen in the 
context of autoimmunity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: A) BKV-infection of a host cell (1), viral-genome release into the nucleus (2). 
Transcription (3), mRNA transport to the cytoplasm (4) and translation into viral proteins, including 
LT-antigen (LT) (5). LT-binding to cellular chromatin (6) and liberation from the host cell (7). B) The 
LT-antigen/cellular chromatin-complex can then be recognized, internalized, processed, and presented 
by B-cells. LT-specific T-cells secrete IL-2 upon recognition and may activate histone-specific T-cells 
in the microenvironment. LT: LT-antigen, HP: histone protein. 
adpted from (Van Ghelue et al. 2003) 
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Upon host cell infection polyomaviruses start with the production of viral proteins, 
including LT-antigen which is able to bind host cell nucleosomes (Andreassen et al. 1999; 
Bredholt et al. 2001). After release of this complex, B-cells may internalize and present both, 
LT-antigen and histone-derived peptides to T-cells (Figure 1.3 A).  
Responder LT-antigen-specific T-cells secrete IL-2 upon peptide recognition and may then 
nonselectively activate autoimmune, histone-specific T-cells which are present in the 
microenvironment (Figure 1.3 B) (Beverly et al. 1992; Jenkins 1992). These histone-specific 
T-cells may clonally expand if histone-derive peptides are presented by antigen presenting 
cells (APC) and if sufficient costimulatory signals are available. Furthermore, these T-cells 
then stimulate the DNA-specific B-cells to proliferate and differentiate into an anti-DNA 
antibody producing plasma cell and result in autoimmunity. 
 
 
1.1.2.2 Late Proteins VP1-3 and Agnoprotein 
The three viral proteins VP1, VP2 and VP3 are expressed late in infection and form a 
icosahedral capsid which encapsulates the viral DNA. The BKV and JCV capsid contains 360 
VP1 monomers arranged in 72 pentameric subunits with each pentamer associated with one 
peptide of either VP2 or VP3 (Figure 1.4) (Liddington et al. 1991). 
 
 
Figure 1.4: Polyomavirus particle consisting of 72 pentameric subunits of VP1 associated with either 
VP2 or VP3. 
(Slavov 2006) 
 
 
BKV-VP3 is identical with the VP2 C-terminus (amino acids 120-351) and consists of a 
DNA binding domain, a nuclear localization signal, and a VP1 interacting domain (Figure 
1.5). Polyomavirus assembly consists of two phases: 1. The "subvirion" assembly phase, 
where pentamerized VP1 associates with VP2 and VP3 in the cytoplasm. All three capsid 
proteins harbor a NLS and the "subvirion" complex is transported into the nucleus. 2. During 
the "virion" assembly phase, the viral genome is packaged. For virion formation, the capsid 
proteins are sequentially arranged on the viral minichromosome. It is hypothesized that six 
DNA binding domains are involved in the packaging of the viral genome: five from the VP1 
pentamer and one from either VP2 or VP3. It has been shown that both minor capsid proteins 
are required for the viral life cycle, including the proper packaging of the genome (Clever et 
al. 1993; Dean et al. 1995; Gasparovic et al. 2006). 
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Figure 1.5: A) BKV-VP2 and B) BKV-VP3. The C-terminal residue is identical (amino acid 120-351) 
and consists of a VP1 interacting domain, a NLS and a DNA-binding domain. The unique N-terminus of 
VP2 is hydrophobic and possesses a fatty acid myristyl group which is added during synthesis. 
adapted from (Clever et al. 1991; Daniels et al. 2006; Nakanishi et al. 2006). 
 
 
Virus-like particles (VLPs) are morphologically similar to natural virus particles, but are 
not infectious due to the lack of genome. VLPs are composed of VP1 alone and are capable of 
self-assembly for both BKV and JCV (Chang et al. 1997; Li et al. 2003). 
Agnoprotein is a small highly basic protein with multiple roles, such as interacting with 
cellular proteins, facilitating the efficient packaging of viral capsid proteins, regulating viral 
transcription and translation. Additionally, agnoprotein was found to interact with LT-antigen 
and downregulate viral gene expression and DNA replication (Cole 1996; Safak et al. 2001).  
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1.2 POLYOMAVIRUSES IN IMMUNOCOMPETENT HOSTS 
 
1.2.1 Polyomavirus BK and JC Infection and Life Cycle 
The mode of transmission of BKV and JCV is not completely resolved but the infection 
occurs most probably via oral and/or respiratory routes during pregnancy, transfusion, or 
transplantation (Hirsch et al. 2003) and occurs asymptomatically in 50%-90% of the 
population (Figure 1.6) (Moens et al. 1995; Knowles et al. 2003). 
 
 
Figure 1.6: Age dependent polyomavirus BK and JC seroprevalence. 
adapted from (Knowles et al. 2003) 
 
 
The infectious life cycle of polyomaviruses can be divided into an early and a late stage. In 
the early stage, the virus interacts with the surface of the host cell, enters the host cell and 
starts to replicate the viral DNA. The late stage includes the assembly of new virions and the 
release of viral progeny which complete the viral replication cycle (Figure 1.7).  
Both viruses, BKV and JCV, bind sialic acid for the host-cell entry (BKV: terminal α2-3-
linked sialic acid, JCV: terminal α2-6-linked sialic acid). While BKV interacts with 
gangliosides GC1b and GT1b, JCV depends on the serotonin receptor 5HT2A to infect cells. 
Host-cell invasion occurs by caveolae-mediated endocytosis (BKV) or via clathrin-coated pits 
(JCV) (Dugan et al. 2006; Gee et al. 2006; Low et al. 2006). Upon host cell entry, 
polyomaviruses are transported to the nucleus by the cytoskeletal transport machinery 
(Dohner et al. 2005). 
In the nucleus, polyomaviruses are uncoated and transcription of the early viral genes, sT-
and LT-antigens, is initiated. Subsequent to early transcription is the switch to DNA-
replication, initiated by LT-antigen, which binds to the origin of replication. LT-antigen is a 
strong activator of the late viral promoter (Henson 1995). Expression and nuclear localization 
of the viral capsid protein VP1-2, leads to the assembly of the virion and DNA packaging. 
The newly packaged virion progeny is then released by a lytic rupture of the host cell 
(Clayson et al. 1989; Imperiale 2001). 
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Figure 1.7: Polyomavirus life cycle. Entry into the host cell and viral DNA-replication in the nucleus 
happens in the early onset of infection. The late onset includes all subsequent events leading to the 
assembly of virions and the release of viral progeny. 
adapted from (Fishman 2002) 
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1.2.2 Polyomavirus BK and JC Latency and Reactivation 
During primary infection (Table 1.3), different host cells, including lymphoid tissues, 
brain, liver, and renourinary tract, are exposed to the polyomaviruses. The most important 
sites are the renal tubular epithelial cells and the urothelial cell layer where BKV and JCV 
reside in a nonreplicative latent state and from where they may reactivate. Reactivation in 
immunocompetent hosts occurs in up to 10% and 40% for BKV and JCV, respectively (Ling 
et al. 2003; Polo et al. 2004). Such a reactivation is characterized by histologically (decoy 
cells) and PCR (DNA) detection of the virus in urine. However, viral replication is effectively 
suppressed in immunocompetent individuals and polyomavirus-associated disease is only 
seen in severely immunocompromised hosts. 
 
Table 1.3: Polyomavirus infections: terminology. 
 Definition 
Primary Infection Initial infection of host with polyomaviruses including viremic spread 
to permissive tissues with insignificant clinical symptoms. 
Latent Infection Dormant asymptomatic infections of permissive cells (e.g. renal 
tubular, transitional cells) following the primary infection; virus 
detection only with molecular techniques. 
Virus-Replication Case with evidence of virus multiplication obtained by detection of 
infectious virus, virions, structural proteins or their mRNA, or cell-
free DNA in nonlatency sites (e.g., plasma or CSF); by cytological 
analysis (of decoy cells); or by histological analysis. 
Virus-Disease Case with histological evidence of BKV-mediated organ pathology 
adapted from (Hirsch et al. 2003; Hirsch 2005; Nickeleit et al. 2006). 
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1.3 POLYOMAVIRUSES IN IMMUNOCOMPROMISED HOSTS 
Diseases caused by polyomaviruses are typically observed in immunosuppressed 
individuals, who are not able to mount a protective immune response to control the viral 
replication. BKV-associated diseases are hemorrhagic cystitis (HC) in hematopoietic stem 
cell transplant (HSCT) recipients, and polyomavirus-associated nephropathy (PVAN) in 
kidney transplant (KT) recipients. JCV is the causing agent for progressive multifocal 
leukoencephalopathy (PML) in human immunodeficiency virus positive (HIV+) patients.  
 
 
1.3.1 Polyomavirus JC: Progressive Multifocal Leukoencephalopathy in 
HIV+ Patients 
PML is a fatal demyelinating disease of the central nervous system in patients with an 
impaired immune system. JCV is the causing agent of PML and brain biopsies show lesions 
which may range from small to several millimeters in diameter. Progression of PML results in 
the enlargement and confluence of these lesions. JCV lytically infects and destroys 
oligodendrocytes, the myelin-producing cells. The infection of astrocytes ends with an 
abortive replication and causes morphological changes in those cells, resembling transformed 
cells (Reiss et al. 2003). Patients with PML suffer from cognitive disturbances, visual 
impairment, sensory loss, speech and language disturbance (Brooks et al. 1984; Berger et al. 
1998). 
PML occurs mainly in HIV+ patients, but is also seen in other individuals with impaired 
immunity: 80% of reported cases have AIDS, 13% suffer from hematological malignancies, 
5% are transplant recipients, and 2% have chronic inflammatory diseases (Koralnik 2006). 
Diagnosis involves brain biopsies which are not always appropriate due to their invasive 
nature. Detection of JCV DNA in cerebrospinal fluid (CSF) by PCR can also be used for 
diagnosis with a diagnostic specificity of 100% and sensitivity of 80% (Hirsch et al. 1998). In 
addition, JCV-DNA is detectable in B-lymphocytes in the brain and can be also found in the 
blood of >95% of PML patients (Houff et al. 1988; Sweet et al. 2002). PML has a significant 
mortality rate in HIV+ patients and before highly active antiretroviral therapy (HAART) the 
median survival rate of AIDS patients was 3.5 months (Berger et al. 1998; Tassie et al. 1999). 
After introduction of HAART the median survival rate increased to 2.2 years in 63% of the 
patients (De Luca et al. 2000; Berenguer et al. 2003). 
Recently, it has been shown that JCV was also reactivated in multiple sclerosis patients 
receiving Natalizumab (Tysabri®). Natalizumab, a monoclonal antibody against integrin, 
significantly increased the risk for developing PML. The incidence of PML was 1 in 1000 
Natalizumab-treated patients, which is substantially lower than the incidence in AIDS patients 
(Berger et al. 2006). 
 
 
1.3.2 Polyomavirus BK: Hemorrhagic Cystitis in Hematopoietic Stem Cell 
Transplant Recipients 
HC is a significant complication following HSCT and is characterized by painful 
hematuria due to hemorrhagic inflammation of the bladder. It is not clear what factors lead to 
HC but chemo-irradiation, cytopenia, viral infections (Adenovirus, Cytomegalovirus, BKV) 
and alloimmune reactions may contribute to the disease (O'Reilly et al. 1981). 
HC can generally be divided into the early and late onset complications. Early onset is 
mainly related to uroepithelial toxicity from conditioning regimen (chemotherapy, 
cyclophosphamide, and busulphan) (Tsuboi et al. 2003). Late onset complications have been 
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linked to several risk factors as unrelated donors, occurrence of graft-versus-host disease, and 
virus infections (Seber et al. 1999; Cesaro et al. 2003; El-Zimaity et al. 2004). 
First evidences of the role of polyomavirus in complications in HSCT recipients was 
discovered in the 1980s with the detection of BKV in urine of those patients (O'Reilly et al. 
1981; Arthur et al. 1986). Nearly 77% of HSCT recipients shed the BKV into urine, but only 
5% - 34% developed HC (Azzi et al. 1999; Priftakis et al. 2003). Later studies showed that 
those patients suffering from HC had a significantly higher BKV load in urine compared to 
the asymptomatic immunocompromised patients (Figure 1.8) (Bedi et al. 1995; Azzi et al. 
1999; Leung et al. 2005). BK viruria in HSCT recipients was as high as 108 -1010 copies/ml 
and patients with a BKV load in urine >107 copies/ml were at higher risk of developing HC. 
Not only the amount of BKV in urine is a risk factor but also the dynamics of viruria over 
time. Eight of 29 patients with HC showed a peak ≥3log higher compared with patients 
without HC (0/39) (Leung et al. 2005). 
 
Figure 1.8: Higher BKV load in urine in patient with HC (diamonds) compared to patients without HC 
(squares). Peaking of BKV load in urine in HSCT patients with HC and low-level BK viruria in HCST 
patients without HC (NS: not significant, *P<0.05 **P<0.01 ; ***P<0.001). 
adapted from (Leung et al. 2005)  
 
 
HC is rare in allograft recipients and AIDS patients, suggesting that HSCT-specific factors 
are necessary for causing the disease (Gluck et al. 1994). It can be suggested that pathogenesis 
of post-engraftment HC is divided into three phases: Phase 1 includes uroepithelial damage 
caused by chemotherapy/irradiation during the conditioning regimen. This is followed by 
uroepithelial regeneration which provides an appropriate cellular milieu for BKV-replication. 
In phase 2, BKV is able to replicate due to the immunosuppressive effects of the conditioning 
as BKV-specific cellular immunity is decreased. BKV-replication then leads to cytopathic 
effects and shedding of the virus in the urine. In phase 3, hematopoietic reconstitution leads to 
the recovery of BKV-specific immunity and this immunological reaction causes extensive 
mucosal damage and severe HC (Binet 2000; Hirsch et al. 2003; Leung et al. 2005). 
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1.3.3 Polyomavirus BK: Polyomavirus-Associated Nephropathy in Kidney 
Transplant Recipients 
BKV is an opportunistic pathogen in KT recipients and causes PVAN in up to 10% of the 
patients with graft loss in up to 80% of the cases (Hirsch 2005). Even though BKV is the 
main causing agent of nephritis in KT recipients, rare cases of PVAN have been reported due 
to JCV or SV40 (Kazory et al. 2003; Wen et al. 2004). The role of BKV-replication in non-
renal solid organ transplantation is not clearly understood, and the best investigated data come 
from KT recipients. 
 
 
1.3.3.1 Risk Factors 
The risk factors for developing PVAN in KT recipients are controversial, but it seems that 
multiple factors are required, including characteristics of the patient (>50 years, male gender, 
white race, BKV-seronegative status prior transplantation, diabetes), the transplant (HLA-
mismatch, prior acute rejection, ischemia), the immunosuppression (triple combination of 
tacrolimus/mycophenolate mofetil/prednisone, drug level, anti-rejection treatment as anti-
lymphocyte globulin), and the virus (serotype, genome mutations, genome rearrangements, 
immune evasion, and fitness) (Figure 1.9) (Hirsch et al. 2003; Hirsch 2005). 
  
Figure 1.9: Risk factors for PVAN development: multiple factors deriving from the virus, patient and 
organ are necessary for development of PVAN. 
adapted from (Hirsch et al. 2003) 
 
 
From all of these risk factors, immunosuppression is generally accepted as the key 
modulator increasing the risk for PVAN. The new potent immunosuppressive drugs, 
tacrolimus and mycophenolate mofetil (MMF), have been significantly associated with BKV-
replication and progression to the disease (Brennan et al. 2005). 
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1.3.3.2 Diagnosis & Monitoring 
Different diagnostic tools, such as detection of decoy cells and BKV-DNA in urine and 
detection of BKV-DNA in plasma, have been used to screen patients for BKV-replication. 
Measurement of BKV-DNA load in plasma correlates closely with allograft involvement, and 
monitoring of the BKV-load seems to be suitable for patient monitoring (Nickeleit et al. 
2000). KT patients with a BKV plasma load of >10'000 DNA copies/ml are at high risk of 
developing PVAN (Hirsch et al. 2001; Hirsch et al. 2002). 
The road to PVAN includes different stations (Table 1.4): 1. Possible PVAN in presence 
of BK-viruria but absence of -viremia, 2. Presumptive PVAN in the presence of viruria and 
viremia, and 3. Definitive PVAN with histological evidence of BKV (Hirsch et al. 2005). 
Definitive PVAN can only be proven by biopsies that have a high specificity but are limited 
due to their invasive nature, their sampling error because of focal distribution and their 
frequent misinterpretation as graft rejection (Randhawa et al. 1999). A lack of detectable 
BKV-DNA in urine practically excludes PVAN due to its high negative predictive value. 
 
 
Table 1.4: Road to PVAN. 
 Urine Plasma Biopsy Definition 
Possible + - - Presence of BK viruria 
Presumptive (+) + - BKV load >10'000 DNA copies/ml in plasma, 
BKV load >107 DNA copies/ml in urine 
Definitive (+) (+) + Histological evidence of allograft involvement 
adapted from (Funk 2007, USGEB, poster number 100) and (Hirsch et al. 2005) 
 
 
Histological outcome of PVAN can be divided into three patterns (A, B or C) according to 
the progression of the biopsy (Table 1.5). Viral cytopathic changes in the kidney result from 
accumulation of newly formed virions in the cell nucleus and cellular lysis. The following 
lesions are multifocally distributed in the graft and PVAN progression results from 
enlargement of these infected foci (Figure 1.10 A) (Drachenberg et al. 2003). To confirm the 
polyomavirus origin of infection, staining for SV40 LT-antigen is usually performed, which 
cross-reacts with BKV- and JCV-LT-antigen (Figure 1.10 B) (Hirsch 2002; Hirsch 2005).  
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Table 1.5: Histological patterns of PVAN. 
A Viral cytopathic changes only, in near-normal renal parenchyma. Negligible or 
absent tubular atrophy, interstitial fibrosis, and inflammation. 
B Combination of viral cytopathic changes and focal/multifocal areas of tubular 
atrophy/interstitial fibrosis/inflammation. 
 B1 <25% of the core shows tubular atrophy/interstitial fibrosis/inflammation. 
The majority of the core lacks features of scarring. 
 B2 26-50% of the core shows tubular atrophy/interstitial fibrosis/inflammation. 
Significant areas of the biopsy lack features of scarring. 
 B3 >50% of the core shows tubular atrophy/interstitial fibrosis/inflammation. 
Only a minority of the core lacks features of scarring. 
C Very scarce viral cytopathic changes in diffusely scarred renal tissue. Extensive 
tubular atrophy/interstitial fibrosis/inflammation involving the entire tissue core 
with no residual areas of nonatrophic tubules. 
adapted from (Drachenberg et al. 2004) 
 
 
 
Figure 1.10: A) Focal infiltrates and enlarged nuclei (arrow) in kidney biopsy, B) Staining for SV40 
LT-antigen which demonstrates numerous viral inclusions (brown) in infected tubular epithelial cells. 
(Schaub et al. 2007) 
 
 
1.3.3.3 Treatment of PVAN 
Current management strategy is to lower immunosuppressive levels to allow 
immunological clearance of BKV-replication. Lowering the immunosuppressive dosage can 
be achieved by three different strategies: 1. Reduction (MMF, tacrolimus and cyclosporine), 
2. Stopping (MMF), or 3. Switching (from FK506 -> cyclosporine or sirolimus, or from MMF 
-> leflunomide) of the drug (Hirsch et al. 2002; Wali et al. 2004). However, reduction of 
immunosuppressants bears the risk for rejection and is histologically difficult to distinguish 
from immune reconstitution inflammatory syndrome (IRIS) (Hirsch et al. 2003). IRIS is a 
strong inflammatory response due to recovery of different immune cells (NK, T-cells) which 
attack the abundant viral antigens and polyomavirus-infected cells. 
There is no established antiviral therapy to control BKV-replication, but some compounds 
including cidofovir, leflunomide, quinolone, intravenous immunoglobulines, and lactoferrin 
have been found to have anti-polyomavirus properties (Figure 1.11) (Josephson 2005; Longhi 
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et al. 2006; Rinaldo et al. 2007). Cidofovir is given intravenously for CMV retinitis treatment 
in AIDS patients but the use of cidofovir is limited due to nephrotoxicity. In vitro studies 
revealed that cidofovir is also effective against mouse polyomavirus and SV40 (Andrei et al. 
1997). The mechanism by which cidofovir mediates anti-polyomavirus activity is not known. 
However the effectiveness in vivo is unclear and prospective studies are missing. 
 
 
Figure 1.11: Compounds with anti-polyomavirus properties. A) Cidofovir, commonly used for CMV 
treatment, B) Leflunomide, approved for use in rheumatoid arthritis, and C) Ciprofloxacin, an 
antibiotic normally used to inhibit the activity of type II bacterial topoisomerase. 
adapted from (Rinaldo et al. 2007) 
 
 
Leflunomide is an antiproliferative agent which limits cellular and humoral immune 
response. It is approved for use in rheumatoid arthritis but has also been found to have 
antiviral properties. Leflunomide may cause severe liver injury which occurs mostly within 
the first 6 months of initiation. In a small study, 17 patients with biopsy-proven PVAN 
underwent treatment with leflunomide. Those patients with a leflunomide blood level of >40 
µg/ml (15/17) cleared the virus or had progressive reduction of BKV. Even though this result 
looks promising the known risk of toxic effects has to be taken into account (Williams et al. 
2005). 
The quinolone antibiotic ciprofloxacin has been shown to suppress BKV-replication and 
thus favors the outcome of HC in HSCT recipients. Quinolones inhibit DNA-gyrase in 
prokaryotes and suppress BKV-replication. None of the patients with significant BK-viruria 
suppression developed HC. Nevertheless, these results have to be validated with a larger study 
group. 
The effect of immunoglobulins as anti BK-virals is not clear. In a study with eight patients 
suffering from PVAN, immunoglobulins were administered and immunosuppression was 
lowered. In follow-up biopsies only one patient was positive for PVAN and after 15 months 
of follow up seven out of eight patients had functional grafts (Sener et al. 2006). 
Unfortunately, it remains unclear whether this outcome was due to the immunoglobulins or 
due to reduced immunosuppressants. 
Lactoferrin is an iron-binding glycoprotein and plays an important role in fighting 
parasitic, mycotic, bacterial and viral infections. In an in vitro assay with Vero (green monkey 
kidney) cells, Longhi et al. could demonstrate that lactoferrin inhibits BKV infection by 
directly binding to viral particles (Longhi et al. 2006). The efficacy of all these compounds is 
controversial and large studies are missing.  
A Cidofovir
Ciprofloxacin
C
B Leflunomide
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1.4 POLYOMAVIRUS-SPECIFIC IMMUNE RESPONSE 
The key element of polyomavirus disease is the disruption of the balance of the viral 
replication and the host immune control. Currently, there is only limited knowledge of the 
humoral and cellular immune response to BKV and JCV. 
 
 
1.4.1 Humoral Immune Response 
BKV-specific neutralizing antibodies reduce the abundance of infectious virus particles, 
prevent a systemic spread of the pathogen in vivo and are directed against the viral capsid 
protein VP1 (Comoli et al. 2006). The exact role of BKV-specific antibodies in a kidney 
transplant setting is controversial. It seems to be that BKV-seropositivity prior to 
transplantation does not protect from BKV-replication and subsequent disease, and that 
antibody titers increase only after resolution of viremia (Comoli et al. 2004; Hariharan et al. 
2005). It has been shown that in pediatric KT recipients a BKV-seronegative status is strongly 
associated with viral replication and progression to PVAN (Ginevri et al. 2003; Smith et al. 
2004). The role of antibodies against JCV is not yet clear, but some reports describe a 
decrease of JCV-DNA in the cerebrospinal fluid (CSF) with a parallel increase of anti-VP1 
antibody titer (Giudici et al. 2000; Guillaume et al. 2000). 
Polyomavirus-specific antibodies clearly deserve more attention, in particular in context of 
using them as biomarkers to monitor KT recipients.  
 
 
1.4.2 Cellular Immune Response 
A protective immune response to viruses is established upon recognition of viral peptides 
by CD8+ (responsible for killing the virus-infected cell) and CD4+ effector T-cells (helping 
B-cells to produce anti-viral antibodies). For viral-peptide recognition by the T-cell receptors, 
the antigen has to be loaded on APC. APCs present antigens on major histocompatibility 
complex (MHC) molecules which appear in two distinct classes: MHC class I (MHC I) or 
MHC class II (MCH II). MHC I are present on all nucleated cells while MHC II are mainly 
present on specialized APCs. Viral peptides are classically bound on MHC I and recognized 
by CD8+ T-cells. CD4+ T-helper (Th) cells are activated by antigens bound on MHC II and 
either activate macrophages (Th1-cells) or B-cells (Th2-cells). Only few BKV- and JCV-
epitopes are known to induce CD8+ or CD4+ cellular immune responses (Table 1.6). 
Epitopes recognized by T-cells may serve as vaccination strategies or adoptive T-cell transfer 
as a therapeutical option for treating or preventing the viral disease. This has already been 
demonstrated for HSCT or SOT recipients who received ex vivo expanded CMV- or EBV-
specific cytotoxic T-lymphocytes (CTLs) (Riddell et al. 1992; Papadopoulos et al. 1994; 
Rooney et al. 1995; Heslop et al. 1996; Comoli et al. 2002). Ex vivo expansion has also been 
developed for BKV-specific CTLs showing that these cells can efficiently lyse BKV-infected 
cells (Comoli et al. 2003). 
Epitope mapping of immunogenic peptides is possible by using peptide libraries for in 
vitro testing, or in a more convenient way, by computer prediction. In vitro epitope mapping 
is very time consuming and expensive, but naturally processed epitopes can be found with 
this method and it is HLA-independent. Computer prediction may miss some epitopes 
because algorithms are not available for all HLA-types. 
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Table 1.6: BKV- and JCV-epitopes inducing a cellular immune response. 
Virus Peptide Length Sequence HLA Reference 
BKV LT25 15aa GNLPLMRKAYLRKCK HLA-B*0702 
HLA-B*08 
(Li et al. 2006) 
 LT27 9aa LPLMRKAYL HLA-B*0702 
HLA-B*08 
(Li et al. 2006) 
 LT362 9aa MLTERFNHIL HLA-A*02 (Randhawa et al. 2006) 
 LT406 9aa VIFDFLHCI HLA-A*0201 (Provenzano et al. 2006) 
 LT410 9aa FLHCIVFNV HLA-A*0201 (Provenzano et al. 2006) 
 LT553 15aa IYLRKSLQNSEFLLE1 HLA-B*0702 
HLA-B*08 
(Li et al. 2006) 
 LT557 15aa KSLQNSEFLLEKRIL2 HLA-B*0702 
HLA-B*08 
(Li et al. 2006) 
 LT579 9aa LLLIWFRPV HLA-A*0201 (Provenzano et al. 2006) 
 LT613 15aa TFSRMKYNICMGKCI3 HLA-B*0702 
HLA-B*08 
(Li et al. 2006) 
 VP1p44 9aa AITEVECFL4 HLA-A*0201 (Chen et al. 2006) 
 VP1p108 9aa LLMWEAVTV5 HLA-A*0201 (Chen et al. 2006) 
JCV LT552 15aa AYLRKSLSCSEYLLE1 HLA-B*0702 
HLA-B*08 
(Li et al. 2006) 
 LT576 15aa KSLSCSEYLLEKRIL2 HLA-B*0702 
HLA-B*08 
(Li et al. 2006) 
 LT612 15aa TFSTMKANVGMGRPI3 HLA-B*0702 
HLA-B*08 
(Li et al. 2006) 
 VP1p36 9aa SITEVECFL4 HLA-A*0201 (Du Pasquier et al. 2003) 
 VP1p100 9aa ILMWEAVTL5 HLA-A*0201 (Koralnik et al. 2002) 
1-5 BKV and JCV homologues peptides 
 
 
The importance of developing an effective immune response to polyomaviruses was also 
illustrated for JCV, the causing agent of PML. CTL-response to JCV-VP1 peptide 
ILMWEAVTL was recognized in five of seven (71%) PML survivors but in zero of six PML 
progressors (Koralnik 2002). Furthermore, PML patients showed reduced JCV-specific CD4+ 
T-cell response and restoration was associated with JCV clearance from CSF which indicates 
the importance of CD4+ response in preventing PML (Koralnik 2002; Gasnault et al. 2003). 
Further studies are needed to understand the interplay of the immune response and viral 
reactivation and replication.  
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2. AIM 
The aims of the present study were: 1. To elucidate the BKV-specific cellular immune 
response to LT-antigen, capsid protein VP1 and agnoprotein in healthy blood donor (HB) and 
KT recipients, 2. To illustrate the interplay between BKV-replication and cellular immune 
response, and 3. To test for cross-stimulation of JCV proteins LT-antigen, VP1 and 
agnoprotein in the same KT patients, due to the 75% homology to BKV. 
To test BKV- and JCV-specific cellular immune response in HB and KT recipients, 
peptide libraries of three BKV-proteins (LT-antigen, VP1 and agnoprotein) and three JCV-
proteins (LT-antigen, VP1 and agnoprotein) were used for PBMC stimulation. The cellular 
immune response to the different peptides was measured by ELISpot assay, using IFN-γ as a 
marker for peptide-specific immune response. 
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3. SUMMARY OF RESULTS 
 
Polyomavirus BK is an emerging pathogen in KT recipients. New potent 
immunosuppressive drugs promote reactivation and replication of BKV and progression 
towards PVAN. PVAN occurs in up to 10% of the KT recipients with a graft loss in up to 
80% of the cases. New potent immunosuppressive drugs, as MMF) and FK506 are risk factors 
for developing PVAN. As no proven antiviral drugs are available, the only therapy of choice 
is the reduction of immunosuppressiva in order to regain BKV-replication control (H. H. 
Hirsch, M. Dickenmann, S. Binggeli, J. Steiger, Schweiz Med Forum 2004; 4:538–541). 
BKV-specific cellular and humoral immune response is not well characterized. Recent 
findings have shown that BKV-seropositive patients prior to transplantation are not protected 
from BKV-replication. In contrast, BKV-specific cellular immune response correlates with 
the diagnosis of PVAN (P. Comoli, S. Binggeli, F. Ginevri, H. H. Hirsch, Transplant 
Infectious Disease Jun 2006; 8(2):86-94, Review). 
The aim of this study was to investigate the interplay of BKV-specific immune response 
and BKV-replication in blood samples of KT recipients. We examined the BKV-specific 
immune response by ELISpot assay in KT. PBMC of KT recipients were stimulated with 
BKV LT-antigen and BKV-VP1 peptide libraries. The BKV-specific immune response was 
measured by the detection of IFN-γ by ELISpot assay. From the results of a pilot study with 
eight patients we were able to deduce that the dynamics of viral-replication rather than the 
viral load correlates with a protective immune response (S. Binggeli, A. Egli, M. 
Dickenmann, I. Binet, J. Steiger, H. H. Hirsch, American Journal of Transplantation, Sep 
2006; 6(9):2218-9). 
To corroborate this previous observation the BKV-specific cellular immunity in 42 KT 
recipients and 10 HB were tested. The KT patients were divided into two groups: patient 
group 1 with an increasing or stable viral load (inc/hi)1 and patient group 2 with a decreasing 
viral load or after resolved PVAN (dec)2. Indeed patients in group 2 showed a significantly 
higher immune response upon stimulation with BKV-LT and BKV-VP1 than patients in 
group 1 (P=0.003, P=0.001, respectively, Wilcoxon, two-sided). Detailed analysis revealed a 
cut-off of >69 SFU/Mio PBMC for BKV LT-antigen, but not for BKV VP1, with 
significantly more KT patients from group 2 (dec) than from group 1 (inc/hi). This cut-off has 
to be validated in a prospective study and also analyzed whether such a cut-off can be used for 
immunosuppressive reduction guidance.  
BKV-specific cell expansion was tested in a short-term culture in the presence of either 
BKV-LT or -VP1. After 9-day culture, PBMC were restimulated with BKV-LT or -VP1 and 
the responses were then compared with responses to direct stimulation (without prior 
cultivation). BKV-LT and -VP1 specific cellular immune responses were significantly higher 
after 9-day cultivation than after direct stimulation (P=0.002, P=0.003, respectively, 
Wilcoxon, two sided). 
Due to high sequence homology between JCV and BKV, JCV-LT and -VP1 overlapping 
peptide pools were used to test PBMC-cross recognition. JCV-LT and -VP1 responses were 
significantly lower than BKV-mediated response (P=0.008, P<0.001, respectively, Wilcoxon, 
two-sided). Comparison of JCV- and BKV-specific responses after 9-day culture revealed that 
the BKV-VP1 response was significantly higher than the JCV-VP1 (P=0.016, Wilcoxon, two 
sided), but no significant difference was observed for LT-antigen (S. Binggeli, A. Egli, S. 
Schaub, I. Binet, M. Mayr, J. Steiger, H. H. Hirsch, American Journal of Transplantation, Mar 
2007; 7:1-9). 
                                            
1 Group 1: increasing or persisting plasma BKV loads of >104 DNA copies/ml and <1.5 log. 
2 Group 2:  decreasing viral load >1.5 log. 
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Agnoprotein, a late viral protein, is highly expressed upon infection. We investigated 
whether agnoprotein is able to induce a BKV-specific immune response and whether it may 
serve as a diagnostic marker. Immunostaining revealed that agnoprotein was highly expressed 
in the cytoplasm of infected cells and was only seen in combination with BKV-LT which is 
located in the nucleus. Interestingly, BKV-agnoprotein specific cellular and humoral immune 
responses were scarcely detected in HB or KT recipients. There are only few published 
studies concerning BKV-agnoprotein, and further investigations are necessary to fully 
understand the function of agnoprotein during infection. (D. Leuenberger, P. A. Andresen, R. 
Gosert, S. Binggeli, E. H. Ström, S. Bodaghi, C Hanssen Rinaldo, H. H. Hirsch, Clinical and 
Vaccine Immunology, Aug 2007; 14(8): 959-968). 
As no antiviral treatment is available for BKV, the only therapy is the reduction of 
immunosuppressive drugs in order to regain immunological control over BKV-replication and 
PVAN. However reduction of immunosuppressants upon PVAN diagnosis bears the risk of 
rejection or inflammatory response to BKV. It is difficult to distinguish between these two 
outcomes because specific markers are yet lacking. Therefore, it is pivotal to record the 
clinico-pathological course of the KT patient in order to correctly diagnose the problem as the 
therapies are completely different. Measuring the BKV-specific cellular immune response 
may support and complement other markers, such as PCR analysis and biopsies, to better 
distinguish between rejection and BKV-specific immune response. (S. Schaub, M. Mayr, A. 
Egli, S. Binggeli, B. Descœudres, J. Steiger, M. J. Mihatsch, H. H. Hirsch, Nephrology 
Dialysis Transplantation, Aug 2007; 22(8): 2386-90). 
Finding the optimal immunosuppressive drug level is crucial for preventing rejection 
(under-immunosuppressed) and viral replication (over-immunosuppressed). Our current study 
showed a cut-off level of 6.65 ng/ml FK506 drug level in blood, dividing those KT patients 
with and without BKV-replication control (ROC-curve: AUC=0.897, sensitivity=78%, 
specificity=86%). If this cut-off is validated by a well designed prospective study, it may 
serve as a guideline to administrate the optimal drug level. (S. Binggeli, 2007, current results). 
BKV-specific epitopes have received considerable attention in the last five years. We 
started with the epitope mapping in a kidney patient with the most common HLA-type: HLA- 
A*01, HLA-B*08. First screening of BKV-LT revealed ten 15aa long peptides with 
immunogenic potential. Three of these ten peptides were further investigated for cross-
recognition with the homologous JCV-peptides. Even though response to the three JCV-
peptides was lower, cellular immune response could be clearly detected. It needs further 
investigation to find more BKV-specific epitopes and also to test the ability of CD8+ T-cells 
to kill BKV-antigen presenting cells. (S. Binggeli, 2007, current results). 
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ABSTRACT 
Cytomegalovirus (CMV) seronegative kidney transplant (KT) recipients (R-) of kidney-
transplants from seropositive donors (D+) are at higher risk for CMV-replication and 
ganciclovir (GCV)-resistance than R+ KT patients. To assess the role of CMV-specific T-cells 
in R+ KT, we studied interferon-γ-producing T-cell frequencies in peripheral blood 
mononuclear cells of 73 KT patients (25 D+R-, 48 R+) undergoing routine testing for CMV-
replication. Median T-cell responses to CMV-lysate, CMV-pp72 and -pp65 peptide pool-
specific antigen preparations were higher in R+ KT than D+R- KT patients, but lower than in 
CMV seropositive healthy donors (P<0.05). CMV-lysate induced higher frequencies than 
pp65 and pp72 peptide pools, but favored CD4+ over CD8+ T-cell responses. By contrast, 
pp72 favored CD8+ responses, while pp65 responses were comparable in both subsets. T-cell 
responses were lower in R+ KT with than without concurrent CMV-replication (pp65 median 
CD4+ 0.00% vs. 0.03%, P=0.001; CD8+ 0.01% vs. 0.03%; P=0.033). CMV pp65-specific 
CD4+ T-cell frequencies >0.03% allowed to identify R+ KT patients free from concurrent and 
from future CMV-replication within 2 months (P=0.021). GCV-resistant CMV-replication 
occurred in 3/48 R+KT patients all of whom had pp65-specific CD4+ T-cells <0.03%. The 
data suggest that CMV-pp65-specific CD4+ T-cells >0.3% may indicate protection from 
CMV replication and GCV-resistance in R+ KT recipients. 
 
 
INTRODUCTION 
Potent immunosuppressive drug regimens have led to a significant decline of acute and 
chronic immune reactions in solid organ transplant (SOT) recipients, with increasing graft 
survival across HLA mismatches (Dharnidharka et al. 2004; Meier-Kriesche et al. 2006). 
However, complications associated with impaired immunity have become more frequent 
(Fishman et al. 1998; Opelz et al. 2006). Cytomegalovirus(CMV) is a notorious infection 
posttransplantation exerting significant direct and indirect effects on graft and patient survival, 
despite the availability of validated strategies for prophylactic, preemptive and therapeutic 
intervention (Reinke et al. 1999; Ljungman et al. 2002; Opelz et al. 2004). The risk of CMV-
replication and disease after SOT is highest in seronegative recipients (R-) of seropositive 
donor (D+) organs and in seropositive (R+) patients exposed to T-cell depleting agents (Kusne 
et al. 1999). This suggests that CMV-specific immunity provides a certain degree of 
protection despite maintenance immunosuppression. Thus, prophylaxis with antiviral drugs 
such as ganciclovir (GCV) or valganciclovir (ValGCV) is recommended (Paya et al. 2004; 
Preiksaitis et al. 2005). However, CMV D+R- SOT are at an increased risk of GCV-resistant 
CMV-replication and disease (Limaye et al. 2000). We hypothesize that the risk may also be 
increased in R+ SOT with low CMV-specific T-cells. Cytotoxic CD8+ T-cells are thought to 
play a major role in terminating CMV-replication, but CMV-specific CD4+ T-cells have been 
linked to long-term antiviral control (Sester et al. 2001; Bunde et al. 2005). In clinical studies, 
responses to CMV-lysate antigens or peptides covering CMV immediate-early (e.g. pp72) and 
late (e.g. pp65) proteins have been used to monitor cellular immunity, but have rarely been 
compared. Here, we studied T-cell responses to different CMV antigens in recently KT 
patients and searched for UL97 mutations in cases with persisting CMV-replication. 
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PATIENTS AND METHODS 
 
PATIENT POPULATION 
A total of 73 consecutive adult CMV D+R-, D+R+ or D-R+ KT patients (n=73) were 
enrolled in this prospective cross-sectional study. Patients were included if CMV-replication 
was submitted to the laboratory for routine testing of CMV in the blood by PCR and/or pp65 
antigenemia. CMV testing was done bi-weekly for the first 4 months, then monthly until 
months 6, to guide preemptive therapy, or weekly for cases where CMV had been suspected 
and that had been found positive (Table 1). D-R- patients were not included (as not routinely 
tested). Patients were assigned to CMV replicating and non-replicating subgroups according 
to whether or not CMV was detected. At the time of laboratory testing for CMV-replication 
and cellular immune responses, triple immunosuppression was administered in 42 patients 
(58%; CMV-replication in 7 cases), dual immunosuppression in 24 cases (33.3%, CMV-
replication in 5 cases) and monotherapy was used in 2 cases, 1 with CMV-replication. 
Tacrolimus was used in 51 patients (71%) with mean trough levels 8.71ng/mL, 13 showing 
CMV-viremia (P=0.038; chi-squared). Mycophenolate mofetil was used in 41 patients (57%) 
with mean trough levels of 2.54ug/mL, 6 showing CMV-viremia (P=0.311; chi-squared). 
Sirolimus was used in 18 patients (25%; mean trough levels 6.92ng/mL, no CMV-replication), 
cyclosporine A in 10 patients (14%; mean trough levels 288ng/mL, no CMV-replication); 
azathioprine in 14 patients (19%, CMV-replication in 3 cases); leflunomide in 3 patients 
(4.2%; CMV-replication in 3 patients); prednisone in 41 patients (57%; mean dosing 
9.3mg/day; CMV-replication in 7 cases). Thirty non-immunosuppressed healthy donors (HB) 
served as control group (17 seropositive HB+: median age 31, range 22-48, 8 males; 13 
seronegative; HB-: median age 32, range 27-60, 9 males). Participants were enrolled in Basel 
and in St. Gallen according to the protocol approved by the IRB (299/06). 
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Table 1: Characteristics of KT patients with and without ongoing CMV-replication. 
 CMV D+R- (n=25, m=50) CMV D+R+/D-R+ (n=48, m=79) 
CMV replication 
(n/total)a 
all 
25 
yes 
(9/25) 
no 
(22/25) 
all 
25 
yes 
(6/48) 
no 
(42/48) 
Age, median years 
(range) 
60 
(18-71) 
63 
(25-71) 
59 
(18-71) 
49 
(21-73) 
53 
(43-70) 
43 
(21-73) 
Gender (m/f) 15/10 6/3 13/9 33/15 5/1 29/14 
Sample date postTx 
median weeks 
(range) 
 
18 
(2-383) 
 
30 
(6-41) 
 
15 
(2-383) 
 
27 
(2-314) 
 
21 
(5-138) 
 
17 
(2-314) 
Induction (n)b 
(%) 
19 
(76.0) 
7 
(77.8) 
12 
(54.5) 
36 
(75.0) 
3 
(50.0) 
33 
(76.7) 
T-cell depleting 
induction (n) c 
(%) 
 
1 
(4.0) 
 
0 
(0.0) 
 
1 
(4.5) 
 
4 
(8.3) 
 
0 
(0.0) 
 
4 
(9.3) 
AR therapy (n)d 
(%) 
8 
(32.0) 
2 
(22.2) 
6 
(27.3) 
21 
(43.8) 
3 
(50.0) 
18 
(41.9) 
T-cell depleting AR 
therapy (n)e 
(%) 
 
3 
(12.0) 
 
0 
(0.0) 
 
3 
(13.6) 
 
11 
(22.9) 
 
2 
(33.3) 
 
9 
(20.9) 
1st CMV load, 
mean (c/ml)a 
 
- 
 
109’900 
 
<300 
 
- 
 
49’588 
 
<300 
1st CMV peak, 
mean (c/ml)a 
 
- 
 
181’811 
 
<300 
 
- 
 
90’009 
 
<300 
1st CMV clearance time 
weeks, median 
(range)a 
 
- 
 
14 
(4-37) 
 
- 
 
- 
 
18 
(7-106) 
 
- 
2nd CMV replication 
(n/total)a 
 
- 
 
1/9 
 
5/22 
 
- 
 
1/6 
 
7/42 
2nd CMV load, 
mean (c/ml)a 
 
- 
 
288’001 
 
9’323 
 
- 
 
1’489 
 
72’581 
2nd CMV peak, 
mean (c/ml)a 
 
- 
 
1’240’000 
 
37’260 
 
- 
 
3’387 
 
311’071 
2nd CMV clearance time 
weeks, median 
(range)a 
 
- 
 
30 
(-) 
 
8 
(1-30) 
-  
22 
(-) 
 
3 
(1-30) 
 
 
AR: acute rejection, ATG: anti-thymoglobuline, n: numbers of patients, m: number of measurements.  
1st CMV episode was either primary (in R-) or secondary replication (in R+). 2nd CMV episode was either 
primary (in remaining R-) or secondary replication (in R+) after determination of CMV-specific cellular 
immunity, after the 1st CMV episode (follow-up ≥3 months). 
a Patients are grouped according to CMV replication at time-point of T-cell response measurement (1st CMV 
episode). 14 patients were measured after seroconversion increasing the numbers to 22. 
b Numbers of recipients with induction treatment. 
c Numbers of recipients with induction treatment based on T-cell depleting antibodies (ATG). 
d Numbers of treated AR episodes. 
e Numbers of patients with AR therapy based on T-cell depleting antibodies (ATG).  
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CMV DIAGNOSTIC ASSAYS 
IgG CMV-serology (AxSymTM Assay, Abbott, Baar, Switzerland) was used according to 
manufactures instructions to identify CMV seropositive and seronegative individuals. CMV-
replication was quantified by standard commercial tests of pp65 antigenemia assay 
(CINAkitTM, Argene, Varilleg, France) in peripheral blood mononuclear cells (PBMC) or by 
quantitative realtime-PCR. In all patients with CMV-antigenemia testing, CMV DNA load in 
whole blood was quantified by CMV-specific real-time PCR. The extraction of DNA was 
performed according to the QIAamp DNA MiniKitTM (QIAGEN, Hombrechtikon, 
Switzerland). CMV-replication was quantified by real-time PCR using the primers TTT TTT 
CTA GGC GCT TCC GA and ACA CTG CGG CTT TGT ATT CTT TAT C, and the Fam-
Tamra labeled probe AGG CGA AGC CGG CGA CGA in validated routine assay. Primers 
and probes were obtained from Eurogentec (Geneva, Switzerland). The linear range of the 
real-time PCR is 10e2 to 10e8 cp/mL. The limit of detection was 300 copies (cp)/mL, and 
1000 cp/mL were used as routine diagnostic cut-off value. All assays were performed in 
triplicates. For quantification, a standard curve was constructed from defined copy number of 
the cloned targets using 10e6 (10e8/mL), 10e4 (10e6/mL), 10e2 (10e4/mL) per 5 uL. DNA 
specimens or controls were added as 5 uL to 20 uL containing 300nM of the respective primer 
pair, 200nM of the respective probe and 12.5 uL of the 2-fold concentrated commercially 
obtained Mastermix containing the AmpliTaq polymerase, dNTP mix with dUTP replacing 
dTTP, Uracyl-N-gylcosylase (AMPerase, Roche) to yield final volume of 25µL. Each DNA 
sample was analyzed after being spiked with 1000 copies of the target pCMV1 to monitor for 
inhibition. The temperature profile consisted of preincubation at 37°C, 15 min to allow for 
enzymatic decontamination of synthetic uracyl-containg amplicons, followed by 95°C; 15 min 
for hot-start activation and 45 cycles of 95°C; 15 sec; 60°C; 60 sec, followed by 7 min at 
72°C. In case of inhibition or unclear results, the DNA was extracted once again and assayed 
as described. Each PCR assay contained routinely non-template controls in triplicates as well 
as one contamination control of human blood donor serum which was taken through the entire 
process of DNA extraction and assayed in triplicates.  
Clinical GCV-resistance was defined as persistent CMV-replication despite adequate 
antiviral treatment for >7 days or as breakthrough replication during prophylaxis (Preiksaitis 
et al. 2005). Genotypic resistance was diagnosed when known mutations in the CMV UL97 
gene were identified using cycle sequencing after a nested PCR strategy with TGC TGC ACA 
ACG TCA CGG TAC ATC and AAA CAG ACT GAG GGG GCT ACT as outer primers (10 
min at 95°C; then 40 cycles of 30 sec at 95°C, 30 sec at 50°C, 1 minute at 72°C and 7 minutes 
extension at 72°C) followed by amplification of two fragments with CGT TGG CCG ACG 
CTA TCA AAT TTC and ACA GCT CCG ACA TGC AAT AAC G (348bp), as well as GTG 
GGT AAC GTG CTG GGC TTT TG and GTG GGT TTG TAC CTT CTC TGT TGC 
(518bp). (10 min at 95°C; then 40 cycles of 30 sec at 95°C, 30 sec at 50°C, 1 minute at 72°C 
and 7 minutes extension at 72°C). Final concentrations in a 50µL reaction volume were 1uM 
primer, 200nM dNTP, 1x Pwo buffer, 1U of Pwo polymerase (Roche, Basel, Switzerland). 
The respective amplicons were isolated from preparative gel electrophoresis for cycle 
sequencing. If UL97 sequences indicated multiple CMV mutants, the amplicons were cloned 
in pGEM3Zf+ plasmid (Promega, Madison, USA), and clones were sequenced. 
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QUANTIFICATION OF CMV SPECIFIC T CELLS 
The measurements of the T-cell responses were 2 ±1.2 times (median 2, range 1-6) in the 
D+/R- group and 1.7 ±1.4 (median 1, range 1-8) in the R+ group (P=n.s.). The frequency of 
CMV-antigen-specific interferon-gamma (IFNγ) producing T-cells by intracellular cytokine 
staining was carried out according to a previously published protocol (Sester et al. 2001) 
except that peripheral PBMC instead of whole blood were used. PBMC were taken before 
medication and tested for CD69+ IFNγ+ response in CD4+CD3+ and CD8+CD3+ T-cells 
after stimulation with three different CMV-antigens: 1) Cell-lysate preparations from CMV 
infected fibroblast cell cultures (4ug/ml, Virion, Rüschlikon, Switzerland), 2) peptide pool 
covering the immediate early protein 1 (pp72), and 3) peptide pool covering the late gene 
tegument protein (pp65). The peptide pools consisted of 15 amino acids (aa) long peptides 
with 11aa overlaps and were used in a final concentration of 2ug/ml (Eurogentech, Geneva, 
Switzerland). Non-infected fibroblast-lysate preparations served as negative control and 
Staphylococcal enterotoxin B (SEB, 1ug/ml, Sigma, Buchs, Switzerland) as positive control. 
PBMC were recovered either from citrate anti-coagulated CPTTM-vacutainers (BD, 
Allschwil, Switzerland) or from EDTA blood using LymphprepTM (Axis Shield, Oslo, 
Norway). PBMC were washed twice in phosphate-buffered saline (PBS) and stimulated with 
CMV-antigens in presence of αCD28/αCD49d (1ug/ml, Becton Dickinson, Allschwil, 
Switzerland) for total 6 hours in RPMI 1640 medium (Sigma) with 10% fetal calf serum, 1% 
penicillin/streptomycin (Gibco, Basel, Switzerland) and 1% glutamax (Gibco). After two 
hours brefeldin A (10ug/ml, Sigma) was added to prevent IFNγ secretion. Cells were washed 
once with PBS (without Ca2+ and Mg2+, pH 7.2), fixed first with 4%, then with 1% 
paraformaldehyde, permeabilized with 0.1% saponin in PBS and stained at room temperature 
in the dark with following antibodies: αCD3, αCD4, αCD8, αCD69 and αIFNγ (all Becton 
Dickinson). At least 30'000 CD3+ lymphocytes were analyzed with FACSCanto (Becton 
Dickinson). The frequency of CMV-specific T-cells was analyzed for each antigen and was 
expressed as percentage of CD69 and IFNγ double positive CD4+CD3+ or CD8+CD3+ cells. 
Negative controls were subtracted to determine the antigen-specific frequency. 
 
 
DATA ANALYSIS 
Data were summarized as mean ±standard deviations (±SD) or as median and ranges where 
appropriate. When Kolmogorov-Smirnov Z Test indicated lack of normal distribution, 
nonparametric tests were used such as the Mann-Whitney U-test, Spearman’s rho correlation 
analysis, and 2-related Wilcoxon test. Categorical markers were analyzed by Fisher’s exact or 
Pearson’s chi-square test. Binary logistic regression’s default and receiver operator 
characteristics (ROC) analysis with Youlden’s Test was used to determine cut-off levels of T-
cell responses. P-values <0.05 were considered as statistically significant. For statistical 
analysis, we used the SPSS 13th version package (SPSS, Chicago, USA). 
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RESULTS 
 
CMV-SPECIFIC CELLULAR IMMUNE RESPONSE IN KT PATIENTS 
PBMC from 73 KT patients undergoing routine testing for CMV replication were analyzed 
for CMV-specific T-cell responses (Figure 1, Table 1). Nine of 25 D+R- KT patients had 
primary CMV-replication at the time of the first CMV-test and a total of 14 seroconverted 
during the follow-up. Six of 48 R+ KT patients had secondary CMV-replication (reactivation) 
at the time of first testing, increasing to a total of 13 during the follow-up. The longer time to 
clear CMV-viremia is remarkable and resulted in part from CMV-persistence due GCV-
resistance and the more sensitive PCR on whole blood as compared to serum. 
 
Figure 1: IFN-γ positive CMV-lysate specific T-cells in HB and KT patients. A) HB and KT patients 
according to CMV serostatus. B) CMV seropositive KT patients according to CMV replication. 
X-axis indicates CD4+ or CD8+ T-cell subsets. Y-axis shows % of IFN-γ positive T-cells after specific 
stimulation with CMV-lysate. Black bars indicate median values. P-values were calculated using non-
parametric Mann-Whitney U-test (*) or Wilcoxon Test (**).  
 
CMV-seropositive R+ had significantly higher CD4+ and CD8+ T-cell responses than 
D+R- KT patients for all CMV-antigens tested (Mann-Whitney U-test, P<0.05, Table 2) 
except for pp72 stimulated CD8+ T-cells where the significance level was not reached 
(P=0.056). In R+ KT patients, T-cell responses were generally higher for CMV-lysate (CD4+ 
0.05%, CD8+ 0.02%) than for the peptide pools of pp72 (CD4+ 0.04%, CD8+ 0.05%) or pp65 
(CD4+ 0.02%, CD8+ 0.02%). CMV-lysate elicited higher CD4+ than CD8+ T-cell responses 
(Wilcoxon signed rank test p <0.005, two-tailed), while no significant differences for CD4+ 
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vs. CD8+ T-cell responses were observed for pp65 peptides (P=0.183, two-tailed) or pp72 
peptides (P=0.255, two-tailed, Figure 1A, Table 2).  
When we compared HB+ and R+ KT-patients, the CMV-specific IFNγ T-cell frequencies 
in seropositive R+ KT patients were significantly lower than in seropositive HB+ for all tested 
CMV-antigens (Mann Whitney U-test, p <0.05), except for pp72-specific CD4+ T-cells where 
the level of significance was barely missed (P=0.0545). In HB+, the median CMV-specific T-
cell responses were significantly higher than in HB- for all CMV-antigens tested. CMV-lysate 
elicited higher responses (CD4+ 1.03%, CD8+ 0.49%) than pp65 peptides (CD4+ 0.11%, 
CD8+ 0.21%) and pp72 peptides (CD4+ 0.08%, CD8+ 0.20%). Of note, CMV-lysate induced 
CD4+ T-cell responses were higher than respective CD8+ T-cell responses (Wilcoxon signed 
ranks test, P=0.018, two-tailed). No significant differences between CD8+ and CD4+ T-cell 
subsets were found for pp65 responses (P=0.528, two-tailed), while a trend for higher CD8+ 
responses was observed for pp72 peptides (P=0.051, two-tailed). Overall, the different 
antigens elicited cellular immune responses as expected for the CMV serostatus of HB. But 
for some of the CMV seronegative patients, a CMV-specific T-cell response above the 
technical cut-off of 0.01% was measured. Taken together, CMV-specific T-cell frequencies to 
CMV-lysate or -pp65 antigens were significantly higher in R+ KT patients than in R- KT 
patients, but lower than in non-immunosuppressed HB+ (Figure 1A). 
 
 
Table 2: CMV-antigen specific IFN-γ producing CD4+ and CD8+ T-cells in HB and KT 
patients. 
 Healthy donors Kidney transplant patients 
CMV-
antigen 
T-cell HB+ 
n=13, m=19 
median 
(range) 
HB- 
n=17, m=17 
median 
(range) 
P-value1 D+R+/D-R+ 
n=48, m=79 
median 
(range) 
D+R- 
n=25, m=50 
median 
(range) 
P-
value1 
CD4+ 
1.03% 
(0.03%-6.19%) 
0.01% 
(0.00%-0.22%) <0.001 
0.05% 
(0.00%-
4.35%) 
0.01% 
(0.00%-0.14%) <0.001 
Lysate 
CD8+ 
0.49% 
(0.00%-4.57%) 
0.00 
(0.00%-0.56%) <0.001 
0.02% 
(0.00%-
1.31%) 
0.00% 
(0.00%-0.07%) 0.003 
CD4+ 
0.08% 
(0.01%-2.83%) 
0.00% 
(0.00%-0.03%) 0.001 
0.04% 
(0.00%-
0.36%) 
0.02% 
(0.00%-0.26%) 0.027 
pp72 
CD8+ 
0.20% 
(0.00%-3.47%) 
0.00% 
(0.00%-0.03%) 0.002 
0.05% 
(0.00%-
0.68%) 
0.03% 
(0.00%-0.34%) 0.056 
CD4+ 
0.11% 
(0.00%-4.70%) 
0.00% 
(0.00%-0.02%) 0.018 
0.02% 
(0.00%-
0.50%) 
0.01% 
(0.00%-0.55%) 0.013 
pp65  
CD8+ 
0.21% 
(0.00%-2.80%) 
0.00% 
(0.00%-0.20%) 0.009 
0.02% 
(0.00%-
0.62%) 
0.00% 
(0.00%-0.25%) 0.001 
 
Data are % of total CD3+ T-cells (30’000). CMV: Cytomegalovirus, HB: healthy blood donors, KT: kidney 
transplant, n: number of patients, m: number of measurements. CMV seronegative KT patients had a D+R- 
constellation. CMV seropositive KT patients included both D+R+ and D-R+ constellations. 1Significant if 
P-value <0.05, Mann-Whitney U-test 
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COMPARING IFNΓ RESPONSES TO DIFFERENT CMV ANTIGENS 
CMV-lysate specific CD4+ and CD8+ T-cell responses correlated well with pp65-specific 
CD4+ and CD8+ T-cell responses (Spearman’s rho 0.564, 2-tailed, P<0.001; and Spearman’s 
rho 0.514, 2-tailed, P<0.001, respectively). No correlation was found between pp65- and 
pp72-specific CD4+ T-cells (Spearman’s rho -0.133, 2-tailed, P=0.347), or between CMV-
lysate specific and CMV-pp72-specific CD8+ T-cell or CD4+ T-cell frequencies (Spearman’s 
rho 0.091, 2-tailed, P=0.530; and (Spearman’s rho -0.263, 2-tailed P=0.065). These results 
suggest that CMV-lysate and -pp65 responses are largely equivalent in PBMC stimulated T-
cell subsets with overlapping specificities of KT patients, while CMV-pp72 seems to stimulate 
a different T-cell population. 
 
 
CMV-SPECIFIC CELLULAR IMMUNE RESPONSES IN SEROPOSITIVE KT PATIENTS WITH CMV-
REPLICATION 
To investigate T-cell responses and their association with antiviral control, we compared 
the frequency of CMV-specific IFNγ responses in R+ KT patients with and without 
concurrent CMV-replication. R+ KT patients with concurrent CMV-replication had 
significantly lower CMV-specific CD4+ and CD8+ T-cell responses compared to R+ KT 
patients without concurrent CMV-replication (P=0.033; Figure 1B, Table 3). We noted two 
exceptions being CD8+ T-cell responses to CMV-lysate (Mann-Whitney U-test, P=0.189) and 
CD4+ T-cell responses to pp72-peptides (P=0.291), which seemed to reflect the antigen-
specific subpopulation bias described earlier (Table 3). We conclude that the data point to an 
inverse correlation of CMV-specific T-cell responses and viral replication, which was most 
consistently captured by the pp65-specific CD4+ T-cell responses.  
 
 
Table 3: CMV-antigen specific IFN-γ producing CD4+ and CD8+ T-cells 
of R+ KT patients with or without concurrent CMV replication. 
CMV-antigen T-cell CMV 
replicating 
(n=6/48) 
median (range) 
CMV 
non-replicating 
(n=42/48) 
median (range) 
P-value1 
 
CD4+ 0.02% (0.00%-0.38%) 0.08% (0.00%-4.35%) 0.011 Lysate 
(m=79) CD8+ 0.01% (0.00%-0.21%) 0.02% (0.00%-1.31%) 0.189 
CD4+ 0.04% (0.00%-0.22%) 0.04% (0.00%-0.36%) 0.291 pp72 
(m=50) CD8+ 0.03% (0.00%-0.24%) 0.07% (0.00%-0.68%) 0.019 
CD4+ 0.00% (0.00%-0.14%) 0.03% (0.00%-0.50%) 0.001 
pp65 
CD8+ 0.01% (0.00%-0.21%) 0.03% (0.00%-0.62%) 0.033 
 
Data are % of total CD3+ T cells (30’000). CMV: cytomegalovirus, R: recipient, n: 
number of patients, m: number of measurements. CMV seropositive KT patients 
included both, D+R+ and D-R+. 1Significant if P-value <0.05, Mann-Whitney U-test. 
 
To identify an IFNγ T-cell frequency associated with protection from CMV-replication, we 
conducted ROC analyses. For CMV-lysate, IFNγ-positive CD4+ T-cell frequencies of >0.1% 
(Figure 2) were associated with absence from concurrent CMV-replication. For CD8+ T-
cells, frequencies of >0.09% were indicated, but the area under the curve (AUC) was only 
0.566 (specificity: 95%, sensitivity: 25%, Fisher exact test P=0.05) For CMV-pp65, the 
respective threshold values for CD4+ (Figure 2) and CD8+ T-cells were >0.03% (AUC 
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CD8+: 0.659, specificity: 80%, sensitivity: 55%, Fisher exact test P=0.04). For CMV-pp72, 
the cut-offs for CD4+ was >0.07% (Figure 3) and CD8+ T-cells was >0.09% (AUC CD8+: 
0.69 specificity: 93%, sensitivity: 45%, Fisher exact test P=0.011), respectively. Thus, CMV 
pp65-specific responses were lower than the ones observed for CMV-lysate or -pp72, but 
provided a best discrimination as captured by the highest ROC AUC. 
 
 
Figure 2: ROC curve analysis - CMV-specific CD4+ T-cell frequency protecting from concurrent CMV 
replication. ROC curves show CD4+ T-cell thresholds which protects from concurrent CMV-replication 
for different CMV-antigens tested. 
AUC, Area under the ROC curve; P-value<0.05 is significant, Fisher exact. 
 
To investigate the degree of protection for subsequent CMV-replication episodes, we tested 
occurrence of CMV-replication during the follow-up period of 3 months. Seven of 43 R+ 
patients without CMV-replication at the initial time-point of measurement had subsequent 
CMV-replication at a median 8 weeks later (range: 6 to 56 weeks) (Table 1) and pp65-
specific CD4+ T-cell frequencies were significantly lower compared to R+ without 
subsequent CMV-replication (median 0.01% vs. 0.03%, Mann-Whitney U-test P=0.021). 
Using the threshold of 0.03% for pp65-specific CD4+ T-cell frequencies, a level >0.03% was 
correlated with protection from subsequent CMV-replication (<2 months, AUC: 0.763, 
specificity: 100%, sensitivity: 47%, Fisher exact test: P=0.036). We could not identify a 
similar cut-off for pp65-specific CD8+ T-cell responses or any of the CMV-lysate or -pp72 
responses (data not shown). 
 
 
GANCICLOVIR-RESISTANCE AND CMV-SPECIFIC CELLULAR IMMUNE RESPONSES 
Among the patients studied, one of 25 D+R- KT patients (4%) developed clinical resistance 
to GCV treatment which was confirmed by the identification of the CMV UL97 mutation 
G598S, in line with the data from the literature (Limaye et al. 2000). In R+ KT patients, 
however, clinical resistance to GCV-treatment was identified in 3 out of 48 (6.25%) cases, 
which is significantly higher than previously noted (Limaye et al. 2000). In these R+ patients, 
CMV-specific T-cells IFNγ responses were <0.03% for CMV-pp65 antigens. The data and 
genotype of the CMV-UL97 sequences are summarized including 6 variants that were 
detected in one patient with three novel in frame deletions (Figure 3). 
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Figure 3: Identified UL97 mutated variants. Boxes indicate gene clusters in phosphokinase UL97 gene 
and show mutations found in 70% of GCV resistant clinical isolates. The entire UL97 region was 
sequenced (amino acids 329-681). Letters indicate amino acids; underlined letters are changed amino acids 
due to gene sequence mutations. GCV-inhibitory concentrations 50% (IC50) associated with mutations are 
listed as uM and -fold increase over wild type (wt) AD169 (1) or Towne (2) strains. 
 
 
DISCUSSION 
Clinical studies have linked the absence of CMV-specific T-cells in SOT recipients to an 
increased risk of CMV replication and disease. This is most obvious for CMV D+R- SOT 
patients (Paya et al. 2004). CMV R+ patients may also develop CMV-replication and disease, 
albeit at lesser frequencies (Sester et al. 2001; Bunde et al. 2005; Sester et al. 2005) which 
might reflect differences in CMV-specific immunity. Our systematicly comparison of CMV-
lysate, -pp65 and -pp72 responses in one of the largest number of R+KT patients indicated 
quantitative and qualitative differences in the response profiles. First, CMV-lysate responses 
were higher than the responses elicited by overlapping 15-mer peptide pools covering pp65 or 
pp72. Contribution of alloresponses to fibroblast cells could not account for this difference as 
since responses to non-infected fibroblast lysate were generally low and always subtracted 
from the individual CMV-lysate responses. More likely, and inline with the most recent 
results by Gerna and colleagues (Lilleri et al. 2007), these quantitative differences may reflect 
the wider range of CMV-antigens contained in CMV-lysate preparations compared to peptides 
restricted to pp65 or pp72. Second, CMV-lysate favored CD4+ T-cell responses, whereas 
CMV-pp72 peptides favored CD8+ T-cell responses. The preferential CD4+ response to 
CMV-lysate has been reported previously by Sester and collaborators (Sester et al. 2001; 
Sester et al. 2002) and may result from uptake, processing and preferential presentation of 
CMV-lysate antigens in an MHC-class II context. CMV derived 15mer peptides might be 
more eligible for direct binding and processing to 8- to 10mer peptides on MHC-class I 
molecules. However, IFNγ responses to pp65-derived CMV 15mers appeared equally frequent 
in both CD4+ and CD8+ T-subpopulations. This difference between pp72 and pp65 suggests 
that sequence-encoded differences in epitopes and processing are likely to be operating as 
well. We conclude that in our series, overlapping peptides covering pp65 provided the best 
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stimulus to induce IFNγ-responses in both CD4+ and CD8+ subpopulations to assay directly 
for CMV-specific T-cells in an HLA-independent clinical setting. 
Regarding the risk of CMV viremia, we found that R+ KT patients with concurrent CMV-
replication had significantly lower CMV-specific T-cell frequencies in PBMC than R+ KT 
patients without concurrent CMV-replication. ROC curve analysis indicated that pp65-
specific CD4+ T-cells frequencies of >0.03% were associated with absence of CMV-
replication, with higher AUC than respective thresholds for pp72 or CMV-lysate. Although 
CD8+ T-cells are known to be required to terminate CMV replication, pp65-directed T-cell 
responses may reflect long-term CMV-protection. By contrast, it can be speculated that pp72-
specific responses operate in short-term replication clearance mediated by CMV-specific 
CD8+ T-cells, but this hypothesis requires further study. 
Previous studies identified a correlation of >0.25% CMV-lysate specific CD4+ T-cells with 
the absence of CMV disease in patients early after transplantation in long-term kidney and 
heart transplant recipients (Sester et al. 2001; Sester et al. 2005). For CMV-pp72, CD8+ T-cell 
frequencies above >0.4% at any time during the first months after lung and heart 
transplantation has been associated with a decreased risk of CMV disease, but not with CMV 
replication (Bunde et al. 2005). An important caveat in defining thresholds resides in the 
dynamic aspect of the virus – host balance, which is exquisitely sensitive to changes in 
immunosuppressive treatments, particularly anti-rejection treatment. In patients with 
concurrent CMV replication, it cannot be decided whether a lower number of CD4+ T-cells is 
the cause or the consequence of CMV-replication. Clearly, positive CMV PCR in blood 
identifies patients at higher risk for CMV-associated complications, and CMV-replication 
dynamics are helpful to predict the further course (Mattes et al. 2005; Funk 2007). However, 
we found that frequencies above the threshold of 0.03% were predictive of CMV viremia-free 
time for the following 8 weeks with a specificity of >93%. This observation may have 
implications in the specific situation where negative CMV PCR results are difficult to 
interpret with regard to future risk. Our data suggest that the detection of CMV-pp65 specific 
CD4+ T-cell frequencies of >0.03% might indicate a reduced risk of future CMV replication 
in stable KT patients (Dickenmann et al. 2001; Dickenmann et al. 2004). With this limitation 
in mind, CMV-specific CD4+ T-cells might serve as a dynamic marker of protection when 
>0.03% and, if validated in future studies, may be useful to complement CMV load 
diagnostics. 
Lack of CMV-specific immunity has been associated with an increased risk of GCV-
resistance CMV-replication (Limaye 2002). Although the improved bioavailability of 
ValGCV appears as a significant safeguard against GCV-resistance, outpatients with changing 
renal function are at an increased risk of suboptimal dosing and emergence of antiviral 
resistance under oral antivirals. In our study, clinical GCV-resistance as defined by Preiksaitis 
et al (Preiksaitis et al. 2005) occurred in 1/25 (4%) D+R- KT patients, at a rate comparable 
with the study by Limaye and colleagues (Limaye et al. 2000). By contrast, the frequency of 
GCV-resistance in our R+ KT patients was significantly higher as described previously with 
3/48 (6.25%). In three of four cases, we confirmed clinical CMV-resistance genotypically by 
identifying mutations in the CMV-UL97 encoding phosphotransferase mutated variants. UL97 
mutations have been reported rarely in R+ SOT patients to date, but not in KT patients yet 
(Lurain et al. 2002; Boivin et al. 2005). Among UL97 mutations, A594V and L595S was 
identified in 30% and 13.3% of all cases, respectively, whereas T569I and G598S mutations 
were rare (Chou et al. 2002; Comoli et al. 2002; Gilbert et al. 2002; Lurain et al. 2002; Gilbert 
et al. 2005). Intermittently negative CMV-loads have been observed in these patients, yet 
pp65-specific CD4+ T-cell frequencies remained <0.03% over prolonged periods. Although a 
low CMV-specific CD4+ T-cell response cannot be used as exclusive parameter to predict the 
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emergence of GCV-resistance in R+ KT patients, its use as risk factor may warrant further 
investigations. 
The limitations of our study are the cross-sectional approach and the relatively small 
sample size of KT patients. In addition, variations associated with the laboratory techniques 
may preclude the adoption of our threshold values by other institutions without further 
standardization. Nevertheless, our data were obtained from studying KT patients in the routine 
clinics and therefore may warrant further studies in larger, preferably prospective settings. In 
summary, monitoring of CMV-specific T-cell frequencies may identify R+ KT patients at risk 
for CMV-replication and resistance. Provided further corroborating evidence, thresholds may 
enter clinical validation and improve decisions concerning duration and dosage of antiviral 
prophylaxis. 
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5. CURRENT PROJECTS 
 
5.1 Influence of Immunosuppressive Drugs Cyclosporine and FK506 on BKV-Specific 
Cellular Immune Response in Kidney Transplant Recipients 
 
5.2 Epitope Mapping of BKV-Proteins: LT, VP1 and Agno of a HLA-A*01, HLA-A*03, 
HLA-B*08, HLA-B*51, HLA-DR*19, HLA-DR*11 Kidney Patient with Past 
Polyomavirus- Associated Nephropathy 
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5.1 INFLUENCE OF IMMUNOSUPPRESSIVE DRUGS CYCLOSPORINE 
AND FK506 ON BKV-SPECIFIC CELLULAR IMMUNE RESPONSE 
IN KIDNEY TRANSPLANT RECIPIENTS 
 
INTRODUCTION 
Polyomavirus BK (BKV) is the causing agent of polyomavirus associated nephropathy 
(PVAN) in up to 10% of the kidney transplant (KT) patients with a graft loss in up to 80% of 
cases (Hirsch 2005). The increase of incidence for PVAN correlates with the administration 
of the new potent immunosuppressiva (IS) such as FK506 and MMF (Brennan 2004). As no 
antiviral treatments are available, the only therapy is IS reduction in order to regain BKV-
specific immunity for the control of viral replication. We have recently evaluated a cut-off of 
69 spot forming units (SFU) per million PBMC for BKV-LT specific cellular immune 
response by ELISpot assay (ESA). This cut-off included most of the KT recipients with 
decreasing or absent plasma BKV loads indicating replication control by BKV-specific 
immunity (Binggeli et al. 2007). The balance between BKV-specific cellular immune 
response and control of viral replication may be shifted in favour of viral replication by 
intense IS. Therefore, adjustment of IS drug levels are crucial for BKV-replication control and 
have to be evaluated individually for each patient. 
Our aim was to establish a system that allowed us to evaluate correlations between IS drug 
levels and the BKV-specific immune response in KT patients, including dose dependence of 
IS, especially with regard to the previously defined cut-off of >69 SFU/106 PBMC. 
 
 
STUDY PARTICIPANTS AND METHODS 
Forty-two KT patients3 (median age 54 years, range 21–65) were enrolled from March 3 to 
October 10, 2006, with written informed consent (Ethics Committee of the Basel Cantons 
235/06). Administration of IS drugs (mg/day) and IS drug levels in plasma (ng/ml) are 
summarized in Table 1. According to our previous analysis of plasma BKV load dynamics in 
KT patients, sampling density and individual fluctuations, we considered plasma BKV load 
changes of >1.5log10 units as significant for the purpose of this study. KT patients were 
divided into two groups according to the changes in plasma BKV load at the time of PBMC 
testing for BKV-specific interferon-g (IFN-γ) production. Group 1 included all KT patients 
with increasing plasma BKV loads (n=5) or persisting BKV loads with past BKV loads of 
>104 copies (cp)/mL and <1.5log10 decline (n = 17) at the time of PBMC testing. Group 2 
included KT patients with ongoing BKV viremia at the time of PBMC testing, but declining 
plasma BKV loads of >1.5log10 decline (n = 13) or past BKV viremia (n = 7) at the time of 
PBMC testing, the latter with histologically confirmed PVAN at a median of 20 months 
(range 5–75 months) (Binggeli et al. 2007). 
 
 
ELISPOT ASSAY (ESA) FOR IFN-γ DETECTION 
BKV- and JCV-specific cellular immune responses were determined by measuring IFN-γ 
secretion upon stimulation of PBMC with viral overlapping peptide pools (OPP) in an ESA. 
For this 96-well multiscreen filter plates (MSIPN, Millipore, Volketswil, Switzerland) were 
coated with 100 µL (10 µg/mL) coating IFN-γ antibody (1-D1K, Mabtech, Hamburg, 
Germany) and incubated over night at 4◦C. 
                                            
3 These patients were the same participants in the study of Binggeli et al. 2007. Data were used to perform first 
analysis for IS experimental set up. 
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PBMC were seeded in triplicates at 2.5 × 105/well with or without peptides (2 µg/mL) and 
at 2.5 × 104/well with Staphylococcus enterotoxin B (SEB; SIGMA, 1 µg/mL) as positive 
control, and incubated over night at 37◦C/5% CO2. Plates were washed five times with 
PBS/0.05% TWEEN 20 (SIGMA) and incubated for 2 h at room temperature with 100 µL (1 
µg/mL) biotinylated detection IFN-γ antibody (7-B6-1 biotin, Mabtech), washed five times 
and incubated for 1 h at room temperature with 100 µL (1 µg/mL) of Streptavidin ALP 
(Mabtech). Spots were developed by adding 100 µL of BCIP/NBT (Calbiochem, Luzern, 
Switzerland) for 10 min. IFN-γ spots were counted by using an ELISpot reader (AID, Büron, 
Switzerland). The number of spot forming units (SFU) 106 PBMC per well was calculated 
from triplicates after subtraction of the negative control. 
CMV-pp65 OPP was used in order to establish new protocols as CMV-specific cell 
frequency is higher than to BKV-specific cell frequency and thus easier to detect. 
 
 
STATISTICAL METHODS 
Nonparametric statistical tests were performed using SPSS (Version-14) to account for 
sample size and non-normal distribution of data. Comparison of the study groups was 
performed by the two-sided Mann–Whitney U-Test. Correlations between paired samples 
were evaluated by the two-sided Wilcoxon signed ranks sum test. Data were expressed either 
as mean ± standard deviation (SD) or as median and range. Correlation between IS and BKV-
specific cellular immune responses were calculated using Spearman's rho correlation 
coefficient (one-sided). Only P-values <0.05 were considered to be statistically significant. 
Box plots depict the median and the interquartile ranges, outliers are plotted above or below 
the whiskers. 
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RESULTS 
 
IS LEVEL IN KT PATIENTS 
Table 1: Study participants and immunosuppressive drugs. 
 Age CsA3 FK5064 MMF5 Sirolimus CsA3 FK5064 MMF5 Sirolimus 
 years mg/day mg/day mg/day mg/day ng/ml ng/ml ng/ml ng/ml 
Group 11 
N=22          
Mean 54 150 5 976 3 224 8 3 5 
SD ±14 ±50 ±3 ±441 ±2 ±186 ±2 ±2 ±2 
Median 54 150 5 1000 3 187 8 2 5 
Min 21 100 2 360 1 60 5 1 3 
Max 72 200 12 2000 4 426 12 6 7 
          
Group 2 2 
N=20          
Mean 52 173 3 875 3 116 5 3 5 
SD ±12 ±77 ±2 ±358 ±1 ±41 ±2 ±2 ±2 
Median 54 168 2 875 3 136 5 2 5 
Min 26 100 2 250 1 61 1 1 3 
Max 66 300 8 1500 4 153 8 7 8 
1Group 1: KT patients with increasing or high stable high viral load, 2Group 2: KT patients with 
decreasing viral load or past PVAN, 3CsA: cyclosporine A, 4FK506: tacrolimus, 5MMF: mycophenolate 
mofetil. 
 
 
KT patients were divided into two groups: group 1 included patients with an increasing or 
stable high plasma viral load and group 2 included patients with a decreasing plasma viral 
load or after resolved PVAN. IS administration in mg/day is listed on the left side of Table 1 
and IS concentration in ng per ml (ng/ml) plasma is listed on the right side of the table. 
 
 
COMPARISON OF DIFFERENT IMMUNOSUPPRESSIVE DRUGS 
Comparison of group 1 (inc/hi) and group 2 (dec) showed no differences in the 
administration of IS drugs per day (mg/ml) of cyclosporine (CsA), tacrolimus (FK506), 
mycophenolate mofetil (MMF), and sirolimus. Detection of IS in plasma revealed only for 
FK506 a significantly higher concentration (Table 2). 
 
Table 2: Comparison of group 1 (inc/hi) and group 2 (dec) and IS drug level 
administered per day (mg/day) and in plasma (ng/ml). 
 CsA1 FK5062 MMF3 Sirolimus CsA1 FK5062 MMF3 Sirolimus 
 mg/day mg/day mg/day mg/day ng/ml ng/ml ng/ml ng/ml 
P-value4 0.905 0.122 0.670 1.000 0.548 0.005 0.963 0.730 
1CsA: cyclosporine A, 2FK506: tacrolimus, 3MMF: mycophenolate mofetil, 4P-value: significant if <0.05, 
Mann-Whitney U-Test, two-sided. 
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CORRELATION OF IS DRUG LEVEL AND BKV-SPECIFIC CELLULAR IMMUNE RESPONSE 
We tested the correlation of IS drug level in plasma and BKV-specific cellular immune 
response of KT patients by calculating Spearman's rho coefficient (rs, one-sided). Immune 
response of BKV-LT and -VP1 was either correlated with CsA, FK506, MMF or sirolimus. 
Except for BKV-VP1/FK506 (P=0.002), no correlation could be found (Figure 1). However, 
the clustering of group 1 (inc/hi) data points towards the right side of the panel suggested a 
FK506 cut-off to be critical for BKV-replication control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Correlation between different IS drug levels in plasma and BKV-specific cellular immune response 
to LT and VP1 in KT patients. A) Cyclosporine A and tacrolimus, B) Mycophenolate mofetil and sirolimus. 
Patients with an immune response >69 SFU/106 PBMC were mostly able to control BKV-replication (Binggeli 
et al. 2007). Negative values indicate a negative correlation, rs: Spearman's rho coefficient (one sided), **: 
P<0.005 (significant). Missing data points are zero. 
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A ROC-curve analysis revealed a cut-off of 6.65 ng/ml FK506 with a sensitivity of 78% 
and specificity of 86% (AUC: 0.897). KT patients receiving FK506 (16/42, 14.3%) were 
divided into two groups: those with <6.65 ng/ml and those with >6.65 ng/ml FK506 
concentration in plasma. Patients who with a plasma level of >6.65 ng/ml had a significantly 
lower BKV-VP1 specific immune response (30 SFU/106 PBMC, range 0-243 SFU/106 
PBMC) than those patients with FK506 plasma level <6.65 ng/ml (193 SFU/106 PBMC, 
range 12-1432SFU/106 PBMC) (P=0.038, Mann-Whitney U-Test, two-sided) (Figure 2). No 
difference could be found for BKV-LT (P=0.442). From 16 KT patients receiving FK506, 9 
were in group 1 (inc/hi) and 7 were in group 2 (dec). Almost all KT patients with increasing 
BK-viral load (7/9, 78%) had a >6.65 ng/ml FK506 plasma concentration whereas only one 
KT patient (1/7, 14%) with decreasing BK-viral load had a FK506 plasma level >6.65 ng/ml.  
 
 
 
Figure 2: A) ROC-curve analysis: AUC: 0.897 and B) cut-off of 6.65 ng/ml for FK506 plasma level. C) 
BKV-VP1 response was significantly lower in patients of group 1 than group 2 (P=0.038). No differences 
for BKV-LT (P=0.442). D) KT patients in group 1 (inc/hi) had a higher FK506 level in blood than 
patients in group 2 (dec) (P=0.005), Mann-Whitney U-Test, two-sided. 
 
 
ESTABLISHMENT OF ESA FOR BKV-SPECIFIC CELLULAR IMMUNE RESPONSE 
MEASUREMENT UNDER INFLUENCE OF IS 
Since FK506 seems to correlate with the cellular immune response, we established an ESA 
for this calcineurin inhibitor. CsA was included for the ESA establishment as it also targets 
the calcineurin phosphatase. The influence of IS drugs on the cellular immune response was 
measured by detection of IFN-γ secreting cells upon stimulation of PBMC from KT patients 
with BKV-LT and -VP1 overlapping peptide libraries. FK506 and CsA were added to PBMC 
in a serial dilution. 
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For the establishment of the method, following tests had to be performed: 1. IS serial 
dilution, 2. Precoating vs. non precoating of the ELISpot membrane with IS, 3. Prestimulation 
with antigen vs. non prestimulation, 4. Stimulation with BKV-VP1 in BKV-seropositive HB, 
and 5. Stimulation of CD4+ or CD8+ depleted PBMC with CMV-pp65. 
 
 
IS SERIAL DILUTION & PRECOATING 
Serial dilution and precoating of ELISpot membrane for 2h with FK506 or CsA was 
performed in the same experiment. PBMC were stimulated with 2 ug/ml SEB over night. 
During this time PBMC were incubated with either FK506 (0, 10, 20, 40, 80, 120, 160, or 200 
ng/ml) or CsA (0, 250, 500, 1000, 1500, 2000, 2500 or 4000 ng/ml). Results are either given 
in SFU/106 PBMC or in percent for cell reactivity. In general, precoating of ELISpot plates 
with CsA or FK506 induced a lower immune response compared to ELISpot plates which 
were not precoated with CsA or FK506 (Figure 3). Already a FK506 concentration of 10 
ng/ml showed very low cell reactivity (2%). 
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Figure 3: Serial dilution of CsA and FK506. PBMC were stimulated with SEB over night and 
simultaneously incubated with IS drugs with different concentrations. ELISpot plates were either 
preincubated with the according IS or added together with the peptides. A) SFU/106 PBMC for CsA and 
FK506, B) Percent cell reactivity depending on IS drug concentration. 
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PRESTIMULATION WITH ANTIGEN 
As FK506 concentration proved to be too high in the first set-up, the same experiment was 
repeated in the range of 0-15 ng/ml FK506. Simultaneously, it was tested if immune response 
to SEB is higher if PBMC were prestimulated for 4h before adding FK506 (no data available 
for CsA) (Figure 4). Immune response increased from 0 ng/ml to 2 ng/ml (2h precoating: 804 
SFU/106 PBMC - 898 SFU/106 PBMC, 0h precoated: 748 SFU/106 PBMC - 926 SFU/106 
PBMC) and decreased to 390 SFU/106 (2h precoated) and 192 SFU/106 PBMC (0h 
precoated), respectively. Four hours preincubation with SEB induced a higher response than 
without preincubation. 
 
 
Figure 4: Serial dilution of FK506 with a concentration of 0 - 15 ng/ml. PBMC were either 
prestimulated for 4h with SEB before FK506 was added (blue line) or SEB was added together with 
FK506 (red line). 
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STIMULATION WITH BKV-VP1 
The BKV-VP1 specific immune response was tested with following conditions: 2h 
preincubation of ELISpot plates with CsA or FK506, PBMC stimulation with BKV-VP1 over 
night without prestimulation. BKV-VP1 specific response decreased from 162 SFU/106 
PBMC to 42 SFU/106 PBMC with increasing CsA concentration (0-3000 ng/ml) and from 83 
SFU/106 PBMC to 5 SFU/106 PBMC with increasing FK506 concentration (0-15 ng/ml) 
(Figure 5). 
 
 
 
Figure 5: Serial dilution of A) CsA and B) FK506. PBMC were stimulated with BKV-VP1 over 
night and simultaneously incubated with IS drugs with different concentrations. 
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CD4+ AND CD8+ DEPLETED PBMC 
To distinguish between CD4+ and CD8+ T-cell derived IFN-γ response, PBMC were 
depleted by MACSbeads and then stimulated with CMV-pp65. Additionally not depleted 
(total) PBMC were also stimulated. IFN-γ secretion of total PBMC was highest (CsA: 856 
SFU/106 PBMC, FK506: 770 SFU/106 PBMC) followed by PBMC without CD8+ (blue line; 
CsA: 420 SFU/106 PBMC, FK506: 418 SFU/106 PBMC) and PBMC without CD4+ (red line; 
CsA: 94 SFU/106 PBMC, FK506: 90 SFU/106 PBMC). Cell reactivity was similar for total 
PBMC, PBMC CD4- and PBMC CD8- (Figure 6). 
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Figure 6: CD4+ (red line) and CD8+ (blue line) depleted PBMC. Immune response of total PBMC 
(black line) was highest for both, CsA and FK506 treated cells. CD4+ depleted PBMC immune 
response was lowest for CsA and FK506. 
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FINAL PROTOCOL 
Taking all results into account, following protocol can be followed to test the influence of 
IS on BKV-specific cellular immune response: 1. Preincubate ELISpot plates for 2h with 
either CsA or FK506, 2. Add PBMC together with the desired antigen and incubate over 
night. The next day, wash and develop ELISpot plates (Figure 7). BKV-LT and -agnoprotein 
have not been tested yet and remain open for establishment. 
 
 
 
Figure 7: ELISpot plates are first incubated with CsA or FK506 for 2h and then PBMC together with the 
antigen are added and incubated over night. Next day the ELISpot plate can be washed, developed and 
analyzed. 
 
 
DISCUSSION 
Immunosuppression is crucial for antirejection treatment in the transplant setting. 
Unfortunately, one of the side effects might be loss of viral-replication control. It is difficult 
to find the optimal immunosuppressive dose level for each patient, and the optimal dose also 
varies over time as drug concentration in the first months posttransplantation is highest and is 
decreased afterwards. 
We hypothesize a negative correlation for IS and immunity. In our study we could show 
that FK506 plasma concentration had a significantly negative correlation with the BKV-VP1 
specific immune response (rs=-0.644, P=0.002). Sester and colleagues recently reported that a 
higher drug level of CsA and FK506 correlated with an increased incidence of CMV-
replication and -complication not only in KT-patients but also in lung transplant recipients 
(Sester et al. 2005). 
Our study is by far not completed and tests with other immunosuppressants like MMF and 
sirolimus have to be performed to evaluate the influence of each drug on the BKV-specific 
immune response. Furthermore, the preliminary cut-off of 6.65 ng/ml FK506 plasma level has 
to be confirmed by a larger study cohort and may serve as a marker for therapeutical 
decisions. 
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5.2 EPITOPE MAPPING OF BKV-PROTEINS: LT, VP1 AND AGNO OF 
A HLA-A*01, HLA-A*03, HLA-B*08, HLA-B*51, HLA-
DR*19, HLA-DR*11 KIDNEY PATIENT WITH PAST 
POLYOMAVIRUS- ASSOCIATED NEPHROPATHY 
 
INTRODUCTION 
Virus-specific cellular immunity is crucial for the control of viral-replication and the 
prevention of disease (Redpath et al. 2001). Latent viruses like Epstein Barr Virus (EBV), 
cytomegalovirus (CMV), and polyomaviruses BK and JC (BKV, JCV) require continual 
surveillance by the immune system. Certain epitopes of viral peptides loaded on MHC class I 
and class II are recognized by CD8+ and CD4+ T-cells, respectively. Upon recognition, 
CD4+ and CD8+ T-cells have different modes of action: while CD4+ T-cells activate either 
macrophages (Th1-cells) or B-cells (Th2-cell), CD8+ T-cells kill the infected cells by 
releasing perforin and granzymes (Kagi et al. 1996; Edwards et al. 1999; Barry et al. 2000). 
Viral epitopes recognized by T-cells may serve for adoptive T-cell transfer (Figure 1) and 
treatment of chronic viral infections, virus-mediated diseases, and virally-induced cancers. 
Adoptive T-cell transfer remains as a therapy option particularly for viruses resistant to 
antivirals (Walter et al. 1995; Heslop et al. 1996). 
Polyomavirus BK may cause polyomavirus-associated nephropathy (PVAN) in up to 10% 
of kidney transplant (KT) patients with graft loss in up to 80% of the cases (Hirsch 2005). 
Antiviral treatment is not available and adoptive T-cell transfer may serve as an alternative 
therapeutical option. Ex vivo expansion of BKV-specific CD8+ T-cells was recently shown to 
be efficient in lysing BKV-infected cells (Comoli et al. 2003). In the last five years, several 
BKV- and also JCV-epitopes from early protein large T (LT) -antigen and viral capsid protein 
1 (VP1) were published for different HLA-types (Table 1). 
 
 
 
Figure 1: Adoptive T-cell transfer. 1. Blood drawing and T-cell isolation, 2. In vitro stimulation of T-cells 
with antigen pulsed dendritic cells, 3. T-cell clonal expansion over several weeks, and 4. Adoptive T-cell 
transfer into the patient. 
Adapted from (Bleakley et al. 2004) 
 
The aim of our study was to perform epitope mapping of BKV-LT, -VP1, and -agnoprotein 
for the most common HLA-type A*01-HLA-B*08 (Mori et al. 1997). For this we used blood 
samples from a kidney patient with past PVAN and HLA type A*01 and B*08. We used the 
computer program SYFPEITHI to predict BKV-LT, -VP1 and -agnoprotein epitopes for 
HLA-type A*01, A*03, and B*08 in order to compare these epitopes with those found by in 
vitro epitope mapping. As BKV and JCV show high DNA and protein homology (Table 2), 
JCV-LT, -VP1 and -agnoprotein homologous peptides were also tested in vitro. 
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Table 1: BKV- and JCV-epitopes recognized by T-cells. 
Virus Peptide Length Sequence HLA-Type Reference 
BKV LT25 15aa GNLPLMRKAYLRKCK HLA-B*0702 
HLA-B*08 
(Li et al. 2006) 
 LT27 9aa LPLMRKAYL HLA-B*0702 
HLA-B*08 
(Li et al. 2006) 
 LT362 9aa MLTERFNHIL HLA-A*02 (Randhawa et al. 2006) 
 LT406 9aa VIFDFLHCI HLA-A*0201 (Provenzano et al. 2006) 
 LT410 9aa FLHCIVFNV HLA-A*0201 (Provenzano et al. 2006) 
 LT553 15aa IYLRKSLQNSEFLLE1 HLA-B*0702 
HLA-B*08 
(Li et al. 2006) 
 LT557 15aa KSLQNSEFLLEKRIL2 HLA-B*0702 
HLA-B*08 
(Li et al. 2006) 
 LT579 9aa LLLIWFRPV HLA-A*0201 (Provenzano et al. 2006) 
 LT613 15aa TFSRMKYNICMGKCI3 HLA-B*0702 
HLA-B*08 
(Li et al. 2006) 
 VP1p44 9aa AITEVECFL4 HLA-A*0201 (Chen et al. 2006) 
 VP1p108 9aa LLMWEAVTV5 HLA-A*0201 (Chen et al. 2006) 
JCV LT552 15aa AYLRKSLSCSEYLLE1 HLA-B*0702 
HLA-B*08 
(Li et al. 2006) 
 LT576 15aa KSLSCSEYLLEKRIL2 HLA-B*0702 
HLA-B*08 
(Li et al. 2006) 
 LT612 15aa TFSTMKANVGMGRPI3 HLA-B*0702 
HLA-B*08 
(Li et al. 2006) 
 VP1p36 9aa SITEVECFL4 HLA-A*0201 (Du Pasquier et al. 2003) 
 VP1p100 9aa ILMWEAVTL5 HLA-A*0201 (Koralnik et al. 2002) 
1-5 BKV and JCV homologous peptides 
 
 
Table 2: BKV and JCV DNA and protein sequence homology. 
 LT-antigen VP1 Agnoprotein 
DNA 78% 75% 72% 
Protein 83% 78% 59% 
1Clustal W pairwise alignment 
 
 
PILOT STUDY: PARTICIPANTS AND METHODS 
STUDY PARTICIPANTS 
A 66 year old male kidney patient, with HLA-type: A*01, A*03, B*08, B*51, DR*11, 
DR*15 was enrolled for this study. The reason for kidney failure is of unknown etiology but 
might be associated with the use of phenacetin. Kidney transplantation occurred after four 
months of hemodialysis. First evidence of BKV-replication was seen 2 months 
posttransplantation with the detection of decoy cells in urine (502/10 HPF4) and viral load in 
plasma (85'660 DNA copies/ml). Definitive PVAN was confirmed by kidney biopsy 5 months 
after transplantation (plasma viral load: 13'116'320 copies/ml). Nephrectomy occurred 22 
months posttransplantation and the patient returned to hemodialysis. 
As a control group served 22 HLA-typed healthy blood donors (HB) from the 
Blutspendezentrum in Basel, Switzerland (Table 3) which shared only one HLA-type with 
the KT patient. 
 
                                            
4 hpf: high power fields 
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Table 3: HLA-type of HB (numbers in red indicate the same 
HLA-type as for the patient). 
 HLA Type 
No. HLA-A HLA-A HLA-B HLA-B 
1 1 28 35 37 
2 3 0 35 0 
3 2 68 51 60 
4 3 32 21 35 
5 1 35 5 0 
6 2 68 (28) 8 44 (12) 
7 2 29 51 44 
8 1 26 60 65 
9 3 0 5 7 
10 1 24 (9) 7 62 (19) 
11 3 11 7 35 
12 24 32 51 60 
13 11 28 51 53 
14 3 68(28) 14 35 
15 2 26(10) 8 65(14) 
16 3 10 5 7 
17 3 26 7 39 
18 1 2 62(15) 57(17) 
19 1 11 27 57(17) 
20 1 2 7 62 
21 25(10) - 8 - 
22 24 0 8 13 
 
 
COLLECTION OF BLOOD CELLS AND PLASMA 
PBMCs of the patient and of the HLA-typed HB were isolated using CPTTM tubes (Becton 
Dickinson, Allschwil, Switzerland). They were washed, counted, and either used directly for 
IFN-γ ELISpot (ESA), for antigen stimulation and 9-day culture, or cryopreserved in 10% 
DMSO/90% FCS (SIGMA, Buchs, Switzerland). PBMC for ESA were diluted in RPMI/5% 
human serum/1% glutamax/1% penicillin streptomycin (R5AB, SIGMA). 
 
 
BKV AND JCV OVERLAPPING PEPTIDE POOLS 
Overlapping peptide pools (OPP) spanning either large LT, VP1 or agnoprotein coding 
sequences from the BKV-Dunlop strain and from the JCV-Mad 1 strain were used for PBMC 
stimulation. The pools consisted of 180 (BKV-LT), 88 (BKV-VP1), 14 (BKV-agnoprotein), 
170 (JCV-LT), 86 (JCV-VP1), and 15 (JCV-agnoprotein) peptides of 15 amino acids (aa) in 
length with an overlap of 11aa (Eurogentec, Germany). 
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COMPUTER PREDICTION SYFPEITHI 
The computer prediction program SYFPEITHI (www.syfpeithi.de) was used to predict 
epitopes for BKV-LT antigen, -VP1, and -agnoprotein for HLA-A*01, HLA-A*03, and HLA-
B*07. No information was available for HLA-B*51, HLA-DR*11, and HLA-DR*15. 
SYFPEITHI T-cell epitope prediction is based on published motifs and considers the amino 
acids in the anchor and auxiliary anchor position. The score is calculated as following: amino 
acids of a certain peptide are given a specific value depending on their anchor position. Ten 
points are given for ideal anchors, 6-8 points for unusual anchors, 4-6 for auxiliary anchors 
and 1-4 for preferred residues. Negative effect on the binding ability has a negative value 
between -1 and -3 points. The maximal achievable score is 36 (for comparison, the very well-
known epitope GILGFVFTL from influenza A scores 30). 
 
EPITOPE MAPPING STRATEGY 
Single peptides were pooled in two ways: 1. The "complete pool" containing all peptides 
from one protein (BKV-LT; 180 peptides/pool, BKV-VP1; 88 peptides/pool, BKV-
agnoprotein; 14 peptides/pool, and JCV-LT; 170 peptides/pool, JCV-VP1; 86 peptides/pool, 
JCV-agnoprotein; 15 peptides/pool), 2. "Subpools" containing 10 LT- or VP1-peptides/pool 
(Figure 2). As agnoprotein contains only 14 peptides for BKV and 15 for JCV peptides, these 
peptides were therefore tested individually and not in subpools. For BKV-LT 38 subpools and 
for BKV-VP1 19 subpools were tested in total. 
PBMC were first stimulated with BKV-peptide subpools for CD4+ T-cell mapping. Then 
we analyzed them further for single peptide activity. CD8+ T-cells were isolated from PBMC 
and mapped separately by stimulation with peptide loaded dendritic cells. Then, we tested 
single peptides to determine the minimal required peptide length (Figure 3).  
 
 
 
Figure 2: Subpools of BKV-LT and BKV-VP1 containing 10 peptides per pool. Numbers or letters in 
red indicate subpool name, numbers in black are single peptide numbers (e.g. BKV-LT pool A contains 
peptides number 89-98). 
 
 
 
 
 
 
 
 
 
 
 
 
 
POOL 1 2 3 4 5 6 7 8 9 10
A 1 2 3 4 5 6 7 8 9 10
B 11 12 13 14 15 16 17 18 19 20
C 21 22 23 24 25 26 27 28 29 30
D 31 32 33 34 35 36 37 38 39 40
E 41 42 43 44 45 46 47 48 49 50
F 51 52 53 54 55 56 57 58 59 60
G 61 62 63 64 65 66 67 68 69 70
H 71 72 73 74 75 76 77 78 79 80
I 81 82 83 84 85 86 87 88
BKV-VP1 10x10 Pool
POOL 11 12 13 14 15 16 17 18 19 20
K 189 190 191 192 193 194 195 196 197 198
L 199 200 201 202 203 204 205 206 207 208
M 209 210 211 212 213 214 215 216 217 218
N 219 220 221 222 223 224 225 226 227 228
O 229 230 231 232 233 234 235 236 237 238
P 239 240 241 242 243 244 245 246 247 248
Q 249 250 251 252 253 254 255 256 257 258
R 259 260 261 262 263 264 265 266 267 268
BKV-LT 10x10 Pool
POOL 1 2 3 4 5 6 7 8 9 10
A 89 90 91 92 93 94 95 96 97 98
B 99 100 101 102 103 104 105 106 107 108
C 109 110 111 112 113 114 115 116 117 118
D 119 120 121 122 123 124 125 126 127 128
E 129 130 131 132 133 134 135 136 137 138
F 139 140 141 142 143 144 145 146 147 148
G 149 150 151 152 153 154 155 156 157 158
H 159 160 161 162 163 164 165 166 167 168
I 169 170 171 172 173 174 175 176 177 178
J 179 180 181 182 183 184 185 186 187 188
BKV-LT 10x10 Pool
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CD4+ T-cell CD8+ T-cell
PBMC stimulation with
BKV-peptide subpools
CD8+ isolation and expansion with
BKV-peptide pulsed dendritic cells
PBMC stimulation with single
BKV-peptides
PBMC stimulation with single
BKV-peptides
Fine mapping with short
peptides (10 aa, 9 aa, 8 aa)
Cytotoxicity assay
Homologous JCV-peptides
Stimulation with HLA-typed HBStimulation with HLA-typed HB
Homologous JCV-peptides
 
Figure 3: Strategy for epitope mapping. Testing of subpools restricts the number of experiments and 
saves patient's PBMC. Peptide subpools with a positive response can be further analyzed and tracked to 
single peptides. The functionality of CD8+ T-cells can be tested by a cytotoxicity assay. Cross-
recognition with JCV single peptides has also to be considered. 
 
 
ESA FOR IFN-γ DETECTION 
BKV- and JCV-specific cellular immune responses were determined by measuring IFN-γ 
secretion upon stimulation of PBMC with viral OPP. For ESA, 96-well multiscreen filter 
plates (MSIPN, Millipore, Volketswil, Switzerland) were coated with 100 µL (10 µg/mL) of 
coating IFN-γ antibody (1-D1K, Mabtech, Hamburg, Germany) and incubated over night at 
4◦C. 
PBMC were seeded in triplicates at 2.5 × 105/well with or without peptides (2 µg/mL) and 
at 2.5 × 104/well with Staphylococcus enterotoxin B (SEB; SIGMA, 1 µg/mL) as positive 
control, and incubated over night at 37◦C/5% CO2. Plates were washed five times with 
PBS/0.05% TWEEN 20 (SIGMA) and incubated for 2 h at room temperature with 100 µL (1 
µg/mL) of biotinylated detection IFN-γ antibody (7-B6-1 biotin, Mabtech), washed five times 
and incubated for 1 h at room temperature with 100 µL (1 µg/mL) of Streptavidin ALP 
(Mabtech). Spots were developed by adding 100 µL of BCIP/NBT (Calbiochem, Luzern, 
Switzerland) for 10 min. IFN-γ spots were counted by using an ELISpot reader (AID, Büron, 
Switzerland). The number of spot forming units (SFU) per 106 PBMC was calculated from 
triplicates after subtraction of the negative control levels. 
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NINE-DAY EXPANSION OF PBMC 
PBMC (2 × 106/mL) were distributed into 24-well plates and incubated over night at 
37◦C/5% CO2. Nonadherent cells were recovered, washed and adjusted to 2 × 106 cells/mL. 
Adherent monocytes were detached by scraping/pipetting, adjusted to 2 × 106 cells/mL and 
stimulated with 5 µg/mL BKV-OPP for 2 h at 37◦C/5% CO2. Monocytes were washed and 105 
cells/mL were added to 2 × 106 of nonadherent cells. After 9 days at 37◦C/5% CO2, ESA was 
performed as described above using 105 cells/well for peptide restimulation or 2.5 × 104/well 
for SEB stimulation. 
 
 
CD8+ AND CD14+ CELL ISOLATION  
PBMC (125 Mio/ml) were mixed with 20 ul of MACSbeads conjugated to αCD8 or 
αCD14 antibodies (Miltenyi Biotec, Germany) and incubated for 20 minutes. CD8+ or 
CD14+ cells were then isolated by using magnetic separation columns (Miltenyi Biotec). 
Isolated CD8+ T-cells were resuspended in R5AB (SIGMA) and CD14+ in RPMI/10% fetal 
calf serum/1% glutamax/1% penicillin streptomycin (R10, SIGMA). 
 
 
DENDRITIC CELL MATURATION AND CD8+ T-CELL EXPANSION 
Isolated CD14+ cells (500'000 cells/ml R10) were incubated with 1000 U/ml of IL-4 and 
800 U/ml of GM-CSF for 7 days. On day seven 1 µg/ml LPS was added over night for 
dendritic cell maturation. Maturation was tested by FACS analysis (switch from CD14+ to 
CD14- and from CD83- to CD83+). Mature dendritic cells (mDCs: 5x106 cells/ml) were 
pulsed with 5 µg/ml OPP and incubated for 2h at 37°C/5% CO2.  
 
Figure 4: Schematic of CD8+ T-cell expansion. CD8+ and CD14+ cells are isolated from PBMC. 
CD14+ cells are maturated to dendritic cells and pulsed with viral peptides to stimulate and expand 
CD8+ T-cells. 
 
After pulsing, mDCs were irradiated for 610 seconds at 2500 rads. Peptide-pulsed mDCs 
were then added to isolate CD8+ T-cells in a ratio of 1:20. CD8+ T-cells were incubated for 3 
weeks and restimulated weekly with fresh peptide-pulsed mDCs (Figure 4). CD8+ T-cells 
response was tested after each week of expansion.  
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RESULTS 
 
PREDICTIONS WITH SYFPEITHI 
BKV-LT, -VP1 and -agnoprotein sequences from the Dunlop strain were analyzed by the 
SYFPEITHI computer program for potential T-cell epitopes of HLA-A*01, -A*03, and -
B*08. Epitopes with a score of ≥20 are listed in Table 4 and were sorted by BKV-protein, 
HLA-type, and number of amino acids. In total 110 BKV-LT, 53 BKV-VP1 and 10 BKV-
agnoprotein epitopes were found by this method. 
 
Table 4: BKV-LT, -VP1, and agnoprotein epitopes predicted by computer program 
SYFPEITHI. Peptides with a score ≥20 are listed in the table. 
Pos HLA-A*01 nonamers  score Pos HLA-A*01 decamers  score Pos HLA-A*01 11 - mers  score
342  P G D P D M I R Y 27 80  S P E R K M L P C Y 26 159  P L E M Q G V L M N Y 26
213  P S R N E N A R Y 20 191  N T D H K A Y L D K 20 276  G T Q Q W R G L A R Y 24
79  D S P E R K M L P C Y 21
313  R T Q R V D G Q P M Y 21
Total 2 Total 2 Total 4
Pos HLA-A*03 nonamers  score Pos HLA-A*03 decamers  score
135  K V H E H G G G K 28 288  K I R L R K R S V K 33
289  I R L R K R S V K 26 126  M L N L H A G S Q K 30
26  K L L I K G G V E 25 21  P V Q V P K L L I K 23
308  D L I N R R T Q R 25 26  K L L I K G G V E V 23
164  G V L M N Y R S K 24 107  N L L M W E A V T V 23
290  R L R K R S V K N 23 164  G V L M N Y R S K Y 22
27  L L I K G G V E V 22 230  N V P P V L H V T N 21
8  G E C P G A A P K 21 284  A R Y F K I R L R K 21
108  L L M W E A V T V 21 331  E V R V F D G T E R 21
127  L N L H A G S Q K 21 340  R L P G D P D M I R 21
165  V L M N Y R S K Y 21 128  N L H A G S Q K V H 20
259  S L Y V S A A D I 21 188  Q V M N T D H K A Y 20
61  E N L R G F S L K 20 244  V L L D E Q G V G P 20
295  S V K N P Y P I S F 20
Total 13 Total 14
Pos HLA-B*08 octamers  score Pos HLA-B*08 nonamers  score
3  P T K R K G E C 20 252  G P L C K A D S L 27
15  P K K P K E P V 20 28  L I K G G V E V L 25
79  D S P E R K M L 20 62  N L R G F S L K L 22
191  N T D H K A Y L 20 283  L A R Y F K I R L 21
284  A R Y F K I R L 20 290  R L R K R S V K N 21
290  R L R K R S V K 20 3  P T K R K G E C P 20
15  P K K P K E P V Q 20
24  V P K L L I K G G 20
37  E V K T G V D A I 20
91  T A R I P L P N L 20
158  E P L E M Q G V L 20
349  R Y I D K Q G Q L 20
Total 6 Total 12
BKV-VP1 (Total 53)
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Pos  HLA-A*01 nonamers score Pos HLA-A*01 decamers  score Pos HLA-A*01 11 - mers  score
603  R L D S E I S M Y 26 308  K K D Q P Y H F K Y 26 283  C E D V F L L L G M Y 28
545  Q I D F R P K I Y 25 164  T T K E K A Q I L Y 22 163  Y T T K E K A Q I L Y 24
155  R T L A C F A V Y 24 225  K G V N K E Y L L Y 20 459  T F E L G V A I D Q Y 24
165  T K E K A Q I L Y 24 75  G T W S S S E V P T Y 21
269  V S W K L I T E Y 22 224  C K G V N K E Y L L Y 21
234  Y S A L T R D P Y 21 608  I S M Y T F S R M K Y 21
77  W S S S E V P T Y 20
Total 7 Total 3 Total 6
Pos HLA-A*03 nonamers  score Pos HLA-A*03 decamers  score
221  F L I C K G V N K 31 475  D V K G T G A E S K 28
499  R D Y L D G S V K 29 28  P L M R K A Y L R K 26
171  I L Y K K L M E K 28 175  K L M E K Y S V T F 26
341  A V D T V L A K K 27 326  I I F A E S K N Q K 25
231  Y L L Y S A L T R 26 299  N V E E C K K C Q K 24
439  G L L D L C G G K 24 170  Q I L Y K K L M E K 23
509  N L E K K H L N K 24 272  K L I T E Y A V E T 23
603  R L D S E I S M Y 24 273  L I T E Y A V E T K 23
272  K L I T E Y A V E 23 542  F V R Q I D F R P K 23
350  R V D T L H M T R 23 171  I L Y K K L M E K Y 22
465  A I D Q Y M V V F 23 397  C L L P K M D S V I 22
520  Q I F P P G L V T 23 457  R L T F E L G V A I 22
175  K L M E K Y S V T 22 551  K I Y L R K S L Q N 22
452  N L P M E R L T F 22 12  E L M D L L G L E R 21
505  S V K V N L E K K 22 220  S F L I C K G V N K 21
568  R I L Q S G M T L 22 278  A V E T K C E D V F 21
28  P L M R K A Y L R 21 520  Q I F P P G L V T M 21
155  R T L A C F A V Y 21 3  K V L N R E E S M E 20
158  A C F A V Y T T K 21 51  K M K R M N T L Y K 20
288  L L L G M Y L E F 21 236  A L T R D P Y H T I 20
551  K I Y L R K S L Q 21 287  F L L L G M Y L E F 20
3  K V L N R E E S M 20 323  A N A I I F A E S K 20
341  A V D T V L A K K R 20
498  L R D Y L D G S V K 20
677  H L C K G F Q C F K 20
Total 22 Total 25
Pos HLA-B*08 octamers  score Pos HLA-B*08 nonamers  score
417  V P K R R Y W L 35 346  L A K K R V D T L 33
563  F L L E K R I L 29 164  T T K E K A Q I L 32
164  T T K E K A Q I 28 417  V P K R R Y W L F 31
28  P L M R K A Y L 26 126  P P K K K R K V E 27
126  P P K K K R K V 26 135  D P K D F P S D L 26
547  D F R P K I Y L 26 27  L P L M R K A Y L 24
368  H I L D K M D L 25 280  E T K C E D V F L 23
508  V N L E K K H L 23 399  L P K M D S V I F 23
551  K I Y L R K S L 23 445  G G K A L N V N L 23
613  F S R M K Y N I 23 534  V P K T L Q A R F 23
49  E D K M K R M N 22 49  E D K M K R M N T 22
346  L A K K R V D T 22 201  P H R H R V S A I 22
399  L P K M D S V I 22 265  E T K Q V S W K L 22
453  L P M E R L T F 22 361  M L T E R F N H I 22
599  E W K E R L D S 22 599  E W K E R L D S E 22
429  I D S G K T T L 21 128  K K K R K V E D P 21
503  D G S V K V N L 21 368  H I L D K M D L I 21
514  H L N K R T Q I 21 514  H L N K R T Q I F 21
597  I V E W K E R L 21 35  L R K C K E F H P 20
620  I C M G K C I L 21 127  P K K K R K V E D 20
35  L R K C K E F H 20 225  K G V N K E Y L L 20
51  K M K R M N T L 20
97  N E K W D E D L 20
128  K K K R K V E D 20
225  K G V N K E Y L 20
347  A K K R V D T L 20
Total 26 Total 21
BKV-LT-Antigen (Total 110)
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BKV-SPECIFIC CELLULAR IMMUNE RESPONSE OF PBMC 
BKV-LT, -VP1 and -agnoprotein complete pools were used for PBMC stimulation. BKV-
specific cellular immune response was measured by IFN-γ secretion after stimulation over 
night and quantified by ESA. Cellular immunitye was strongest for BKV-VP1 (189 SFU/106 
PBMC), followed by BKV-LT (40 SFU/106 PBMC) and BKV-agnoprotein (5 SFU/106 
PBMC) (Figure 5). 
 
 
Figure 5: PBMC stimulation with different BKV-OPP. BKV-VP1:189 SFU/106 PBMC, BKV-LT: 40 
SFU/106 PBMC, and BKV-agnoprotein: 5 SFU/106 PBMC. 
 
 
Pos HLA-A*01 nonamers score Pos HLA-A*01 decamers  score Pos HLA-A*01 11 - mers  score
all ≤12 all ≤12 all ≤12
Pos HLA-A*03 nonamers  score Pos HLA-A*03 decamers  score Pos HLA-B*08 octamers  score
5  Q L S R Q A S V K 35 55  A L P A V K D S V K 32 47  D G K N K S T T 20
52  S T T A L P A V K 21 13  K V G K T W T G T K 28 49  K N K S T T A L 20
8  R Q A S V K V G K 20 4  R Q L S R Q A S V K 26
51  K S T T A L P A V K 21
45  S V D G K N K S T T 20
Total 3 Total 5 Total 2
BKV-Agnoprotein (Total 10)
ESA with BKV-Complete Pool
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POOL 1 2 3 4 5 6 7 8 9 10
A 89 90 91 92 93 94 95 96 97 98
B 99 100 101 102 103 104 105 106 107 108
C 109 110 111 112 113 114 115 116 117 118
D 119 120 121 122 123 124 125 126 127 128
E 129 130 131 132 133 134 135 136 137 138
F 139 140 141 142 143 144 145 146 147 148
G 149 150 151 152 153 154 155 156 157 158
H 159 160 161 162 163 164 165 166 167 168
I 169 170 171 172 173 174 175 176 177 178
J 179 180 181 182 183 184 185 186 187 188
BKV-LT 10x10 Pool
POOL 11 12 13 14 15 16 17 18 19 20
K 189 190 191 192 193 194 195 196 197 198
L 199 200 201 202 203 204 205 206 207 208
M 209 210 211 212 213 214 215 216 217 218
N 219 220 221 222 223 224 225 226 227 228
O 229 230 231 232 233 234 235 236 237 238
P 239 240 241 242 243 244 245 246 247 248
Q 249 250 251 252 253 254 255 256 257 258
R 259 260 261 262 263 264 265 266 267 268
BKV-LT 10x10 Pool
EPITOPE MAPPING OF BKV-LT-ANTIGEN 
In a second step BKV-LT subpools were used for PBMC stimulation. A total of 38 BKV-
LT subpools were tested for cellular immune response by ESA. Subpools inducing ≥8 
SFU/106 PBMC (corresponds to one standard deviation above background: 4 SFU/106 PBMC 
±4) were considered for further analysis. Totally 10/38 (26%) subpools fulfilled this criteria: 
A, H, O, 6, 7, 8, 11, 12, 15, 16 (Figure 6).  
 
 
Figure 6: PBMC stimulation with different BKV-LT subpools. Subpools inducing a response ≥8 SFU/106 
PBMC (cut-off: one standard deviation above background) were considered for further analysis. 
 
 
Consulting the BKV-LT subpool board revealed 10/180 (6%) potentially immunogenic BKV-
LT single peptides: pp94, pp95, pp96, pp164, pp165, pp166, pp229, pp230, 233, and pp234 
(Figure 7). 
 
A 
 
B pp94: RAAWGNLPLMRKAYL 
pp95: GNLPLMRKAYLRKCK 
pp96: LMRKAYLRKCKEFHP 
pp164: VEECKKCQKKDQPYH 
pp165: KKCQKKDQPYHFKYH 
pp166: KKDQPYHFKYHEKHF 
pp229: NSEFLLEKRILQSGM 
pp230: LLEKRILQSGMTLLL 
pp233: LLLLLIWFRPVADFA 
pp234: LIWFRPVADFATDIQ 
 
Figure 7: A) Potentially immunogenic single peptides (numbers in bold) identified at the intersection of 
two subpools (highlighted in yellow). B) Peptide sequences for the ten peptides. 
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For testing single BKV-LT peptides, PBMC were cultivated for 9-days with pp94, pp95, 
pp96 and then restimulated with single peptides to reach the ESA detection limit. We tested 
pp94, pp95, and pp96. In addition, we investigated whether peptide cross-restimulation is 
possible and cultivated PBMC with either pp94, pp95 or pp96 and restimulated with pp94 (for 
pp955 and pp96), pp95 (for pp94 and pp96), and pp96 (for pp94 and pp96) (Figure 8). 
 
 
Figure 8: BKV-LT single peptides pp94, pp95, pp96 were used for 9-day cultivation of PBMC and 
restimulation for ESA. 
 
No detectable immune response was measured after 9-day cultivation with pp94 and 
restimulation with either pp94, pp95 or pp96. 
 
 
                                            
5 9-day cultivation with pp95 and restimulation with pp94 was not performed due to lack of appropriate cell 
numbers. 
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BKV-AGNOPROTEIN SINGLE PEPTIDES 
PBMC stimulation with single peptides of BKV-agnoprotein was below the detection limit 
of ESA (data not shown). Therefore, PBMC were incubated for 9-days with agnoprotein 
complete pool and restimulated for ESA. BKV-agnoprotein specific response was detectable 
for complete pool and all single peptides except pp8 (Figure 9). 
 
 
Figure 9: PBMC stimulation with different BKV-agnoprotein single peptides. Except for pp8 all peptides 
induced detectable responses (≥8 SFU/106 PBMC). 
 
Table 5: BKV-agnoprotein specific immune response to 
single 15aa long peptides. 
Agno SFU/106 PBMC % of CP1 Sequence 
CP1 70 100% Complete Pool 
pp1 40 57% MVLRQLSRQASVKVG 
pp2 23 33% LSRQASVKVGKTWT 
pp3 10 14% ASVKVGKTWTGTKK 
pp4 37 53% KVGKTWTGTKKRAQR 
pp5 50 71% TWTGTKKRAQRIFIF 
pp6 63 90% TKKRAQRIFIFILEL 
pp7 43 61% AQRIFIFILELLLEF 
pp8 0 0% FIFILELLLEFCRGE 
pp9 90 129% LELLLEFCRGEDSVD 
pp10 13 19% LEFCRGEDSVDGKNK 
pp11 30 43% RGEDSVDGKNKSTTA 
pp12 40 57% SVDGKNKSTTALPAV 
pp13 17 24% KNKSTTALPAVKDSV 
pp14 40 57% TTALPAVKDSVKDS 
1 CP: complete pool 
 
Response to the agnoprotein complete pool (70 SFU/106 PBMC) was defined as maximal 
response (100%). Response to single peptide pp9 was higher (90 SFU/106 PBMC) than 
response to complete pool. All other peptides induced a response between 0 and 63 SFU/106 
PBMC (0-90%) (Table 5). 
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CROSS-RECOGNITION WITH JCV-HOMOLOGUES PEPTIDES 
To test if JCV-peptides were also recognized by BKV-specific cells, complete pools of 
JCV-LT, -VP1, -agnoprotein, and homologous JCV single peptides (pp245, pp246 pp247) 
were used for restimulation after 9-day expansion with the BKV-complete pool and with 
BKV-peptides (pp94, pp95, pp96), respectively (Figure 10).  
 
Figure 10: PBMC stimulation BKV-OPP and their JCV-homologues after 9-day cultivation. Response to 
BKV-antigens were always higher when compared to JCV-antigens. 
 
 
BKV- and JCV-VP1 complete pools induced the highest immune response (4460 SFU/106 
PBMC and 1293 SFU/106 PBMC, respectively) followed by LT (2280 SFU/106 PBMC and 
900 SFU/106 PBMC, respectively) and agnoprotein (47 SFU/106 PBMC and 23 SFU/106 
PBMC, respectively). Cellular immune response after stimulation with BKV-single peptides 
pp94, pp95 and pp96 (600 SFU/106 PBMC, 463 SFU/106 PBMC, and 577 SFU/106 PBMC, 
respectively) was always higher compared to JCV-homologous peptides pp245, pp246 and 
pp247 (283 SFU/106 PBMC, 230 SFU/106 PBMC, and 113 SFU/106 PBMC, respectively). 
 
JCV-Cross Recognition
1
10
100
1000
10000
LT VP1 Agno pp94/pp245 pp95/pp246 pp96/pp247
SF
U
/M
io
 P
BM
C
SF
U
/M
io
 P
BM
C
LT VP1 pp94 pp95 pp96AgnoBKV
JCV pp245 pp246 pp247LT VP1 Agno
 CURRENT PROJECTS: PRELIMINARY RESULTS AND OUTLOOK 
_____________________________________________________________________________  
_____________________________________________________________________  
108 
CD4+ AND CD8+ T-CELL DEPLETION 
In order to differentiate between IFN-γ secretion from CD4+ and CD8+ T-cells, either cells 
were positively selected by MACSbeads. CD4+ or CD8+ depleted PBMCs were stimulated 
with either the BKV-LT or -VP1 complete pool. Lowest IFN-γ secretion was detected in 
CD4+ T-cell depleted PBMC (BKV-LT 51 SFU/106 PBMC and BKV-VP1 80 SFU/106 
PBMC, respectively). CD8+ T-cell depleted PBMC responded to 132 SFU/106 PBMC (BKV-
LT) and 520 SFU/106 PBMC (BKV-VP1) and non-depleted PBMC responded to 97 SFU/106 
PBMC (BKV-LT) and 280 SFU/106 PBMC (BKV-VP1) (Figure 11). 
 
Figure 11: PBMC were depleted from either CD4+ or CD8+ T-cells and stimulated with BKV-LT or -
VP1. Response was lowest after CD4+ T-cell isolation. 
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CD8+ CELL ISOLATION BY MACSBEADS 
To establish CD14+ cell maturation and CD8+ T-cell expansion, PBMC from CMV-
seropositive HB and CMV-pp65 OPP were used. For measuring the CD8+ T-cell specific 
cellular immune response, these cells were positively selected out of PBMC using 
MACSbeads. Additionally, CD14+ cells were also positively isolated and maturated to 
dendritic cells (mDC). The CMV-pp65 complete pool was used to pulse mDC for antigen 
presentation. CD8+ T-cells were co-cultured for three weeks with peptide pulsed mDC 
(restimulation occurred every week with freshly peptide pulsed mDC).  
Dendritic cell maturation was observed by the switch of CD14+/CD83- cells to CD14-
/CD83+ cells using cellular staining and FACS analysis. For maturation, LPS was added over 
night at day 7 (Figure 12). 
 
Figure 12: CD14+ cell isolation from PBMC. CD14+ switched from CD83- to CD83+ cells 
from day 7 to day 8 after adding LPS. 
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CD8+ T-CELL EXPANSION WITH CMV-PP65 
The CMV-pp65 complete pool was used to pulse mDC for CD8+ T-cell expansion over 3 
weeks. For background control, following cells were seeded: pulsed mDC alone, CD8+ T-
cells alone (not expanded), CD8+ T-cells not expanded but stimulated with mDC-pp65 and 
CD8+ T-cells alone (expanded) (Figure 13). Over three weeks, CD8+ T-cells could be 
expanded 60x (week 0: 123 SFU/106 PBMC, week 1: 2383 SFU/106 PBMC, week 2: 5597 
SFU/106 PBMC, and week 3: 7340 SFU/106 PBMC). 
 
 
 
Figure 13: CD8+ T-cell expansion with CMV-pp65 over three weeks. IFN-γ response increased 
60x from week 0 (123 SFU/106 PBMC) to week 3 (7340 SFU/106 PBMC). 
 
CD8+ T-Cell Expansion with CMV-pp65 in a HB
0
2000
4000
6000
8000
mDCpp65 CD8 not expanded CD8 ne mDCpp65 CD8 expanded CD8 exp 
SF
U
/M
io
 P
B
M
C
2 weeks
3 weeks
0 weeks
1 week
-
-
mDC-pp65
CD8+ T-cells
not expanded
-
CD8+ T-cells
not expanded
mDC-pp65
CD8+ T-cells
expanded
-
CD8+ T-cells
expanded
mDC-pp65
 CURRENT PROJECTS: PRELIMINARY RESULTS AND OUTLOOK 
_____________________________________________________________________________  
_____________________________________________________________________  
111 
DISCUSSION 
The knowledge of immunogenic BKV-epitopes may provide valuable information 
regarding vaccine development and for the development of therapies based on adoptive T-cell 
transfer. Our aim was to map BKV-LT, -VP1, and -agnoprotein epitopes in the most common 
HLA-types HLA-A*01, HLA-B*08 (Mori et al. 1997). Epitope mapping is very time 
consuming and expensive. Therefore, epitope prediction by SYFPEITHI is generally 
preferred for identification of new epitopes. The disadvantage of this method lies in the 
restricted availability of HLA-types to test. Furthermore, even with the very well known 
HLA-type A*02, some epitopes will be missed as computer predictions are not 100% reliable. 
Adoptive T-cell transfer with HLA-type dependent epitopes can only be applied to patients 
with the appropriate HLA-type. A HLA-type independent approach can be achieved by using 
overlapping peptide pools or virus infected cell lysate for T-cell transfer, but these methods 
are expensive and time consuming, respectively. 
Using ESA as an in vitro method for epitope mapping, we found ten potentially 
immunogenic epitopes for BKV LT-antigen. Further investigations are needed to evaluate the 
minimal amino acid length inducing an immune response in CD8+ T-cells. Three of these ten 
BKVLT peptides (pp94, pp95, and pp96) were further tested for cross-recognition with the 
homologous JCV-peptides (pp245, pp246, and pp247). It was not of surprise that these JCV-
LT peptides were also able to induce an immune response as they share 12 of 15 aa with their 
BKV-LT homologous peptides. Interestingly, the responses to BKV-VP1 complete pool was 
3.4 fold higher than to JCV-VP1 complete pool (4460 SFU/106 PBMC and 1293 SFU/106 
PBMC, respectively), The differences between BKV and JCV LT-antigen was only 2.5 fold. 
This can be explained by the higher protein homology for LT (83%) than for VP1 (78%). In 
contrast, agnoprotein shows only a protein homology of 59% but BKV-agnoprotein is able to 
induce a response which is only 2 fold higher compared to JCV-agnoprotein. One explanation 
can be that only the N-terminal part is important for T-cell recognition. The N-terminus of 
agnoprotein has a higher homology (84%, amino acids 1-33, Clustal W) compared to the C-
terminus (39%, amino acids 34-71, Clustal W). 
Our data show that we were able to expand BKV-specific cells during 9-day cultivation 
and to measure the immune response by ESA. Current results were encouraging and 
suggested that this project needs more work to track down the different BKV-epitopes. 
Additionally, a cytotoxicity assay needs to be established to test CD8+ T-cell functionality, 
and investigation of JCV cross-recognition has to be performed, too. 
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6 DISCUSSION 
 
6.1 Therapeutic Options for BKV-Replication Control in Kidney 
Transplant Recipients 
PVAN is a complication predominantly seen in kidney transplant recipients, with graft loss 
in up to 80% of patients with advanced stages (Hirsch 2005). It is generally accepted that 
BKV reactivation and progression to PVAN in KT recipients is associated with impaired 
cellular immunity. Our knowledge about the risk factors and impaired BKV-specific immune 
response is limited, making the management of PVAN very difficult. Furthermore, the 
mechanisms of BKV-reactivation are not yet clear, and it also remains obscure why some KT 
recipients develop PVAN while others on the same immunosuppressive regimen do not. The 
only proven therapy to control BKV-replication is by decreasing the dose of 
immunosuppressives (Trofe et al. 2006). The effect of immunosuppression reduction can be 
monitored by BKV load measurements in plasma. 
The case report "Transient allograft dysfunction from immune reconstitution in a 
patient with polyoma BK-virus-associated nephropathy" (Schaub et al. 2007) shows how 
important it is to closely monitor BKV loads in a patient after immunosuppressive dose 
reduction and to observe the clinico-pathological course for therapeutical decisions to achieve 
a good outcome. This patient showed tubulointerstitial inflammation which may either derive 
from allograft rejection or from inflammatory response to the BKV. Because of different 
observations such as BKV-load decline in plasma, only moderate increase of serum creatinine 
and significant reduction of polyomavirus antigen-positive tubular epithelial cells, it was 
concluded that the inflammation derived from BKV-specific immune reconstitution and not 
from rejection. Therapeutical decision is very crucial for the outcome of the kidney allograft 
as rejection and reconstitution syndrome are treated in opposed ways. 
Reduction of immunosuppressive drug doses is very effective in regaining control over 
BKV-replication in 11%-20% of the patients. However, reducing IS inevitably increases the 
risk for rejection (Ramos et al. 2002). For each patient, a certain range may exist where the 
degree of immunosuppressants is neither too high (risk for viral-replication/-reactivation and 
disease) nor too low (risk for rejection) (Figure 5.1). This range may vary among patients due 
to personal factors (genetic background, metabolization rate, etc.), the amount and way drugs 
are administered (oral vs. intra venous) as well as the state of the allograft (cadaveric versus 
living donation, ischemia time, surgical injuries). 
Figure 5.1: Schematic representation of the interplay between immunosuppression (IS), infection and 
rejection. IS is highest directly after transplantation. The higher the IS dose, the higher the risk for viral 
reactivation and disease (red area). The lower the IS, the higher the risk for rejection (blue-violet area). 
Optimal level (green area) of IS with minimal complications. 
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In general we expect that the higher the immunosuppressive drug concentration, the lower 
the immune response. Sester and colleagues showed that the frequency of CMV-specific T-
cells in lung transplant recipients correlated negative with higher levels of 
immunosuppressive drugs and with increased CMV complications (Sester et al. 2005). 
Although our data generally reproduced this pattern, the only significant negative correlation 
was found for FK506 and BKV-VP1 specific cellular immune response (rs=-0.644, P=0.002) 
("Influence of Immunosuppressive Drugs Cyclosporine A and FK506 on BKV-Specific 
Cellular Immune Response in Kidney Transplant Recipients") (S. Binggeli, current 
results). There maybe different reasons for this result: 1. Sampling bias: the number of cases 
is too low. This needs further studies with more KT patients and probably a denser sampling 
scheme; 2. Misfit: the association between IS and immunity is not a linear correlation and 
thus cannot be described by Spearman's rho coefficient, as this test looks only for linear 
correlations. Also this would need more investigation with a higher sample size; 3. Wrong 
surrogate marker: measuring the BKV-specific response is not an adequate marker for testing 
immunosuppressive drug level; 4. Complexity: as too many factors play a role and we cannot 
disentangle them. KT patients usually receive more than one immunosuppressant for 
antirejection treatment and nephrotoxicity of other drugs may also influence the outcome. 
To find a correlation between BKV-specific immune response and IS concentration, an in 
vitro assay may shed light on this question because single immunosuppressants can be tested. 
In line with the a priory hypothesis that IS reduces immune response, our preliminary data 
show a decrease of immune response with increasing levels of IS, independent of the antigen 
(SEB, BKV-VP1 or CMV-pp65). Further studies are needed to reproduce this result with 
other IS such as MMF and sirolimus. 
We found that FK506 plasma levels achieved in a KT patient ranged from 5-12 ng/ml. 
Analysis of the BKV-VP1 specific response in combination with FK506 revealed a cut-off of 
6.65 ng/ml FK506 plasma level. Most KT patients above this cut-off were not able to control 
BKV-replication. Our pilot experiments suggest further studies to clarify, whether or not 
elevated levels of FK506 were associated with more frequent BKV replication. If other IS 
than FK506 play a role for BKV-replication control needs further analysis. 
 
 
6.2 Biomarker for the Monitoring of Kidney Transplant Recipients 
In the clinics as well as in the pharmaceutical industry, there is great interest in identifying 
new biomarkers for: 1. Prognostic purposes to monitor whether and how fast patients develop 
PVAN, 2. Stratification purposes, to predict the outcome of the disease after therapeutic 
intervention, 3.Evaluating the efficacy of therapeutic interventions for individual patients, and 
4. Using it as a non invasive marker for differentiation between immune reconstitution 
inflammatory syndrome (IRIS) and rejection. It would be advantageous to have a prognostic 
marker to define which patient is at risk for rejection before the immune response is strong 
enough to attack the allograft. Although biopsies are the "gold standard", non-invasive 
methods are preferred because biopsies are expensive, locally restricted, bear the risk for 
complications, and are frequency limited. 
The ELISpot technique represents such a non-invasive and more direct method to measure 
the cellular response than staining for HLA-DR positive tubular cells in biopsies is possible 
by using. In "Polyomavirus BK-Specific Cellular Immune Response to VP1 and Large T-
Antigen in Kidney Transplant Recipients" (Binggeli et al. 2007) we could demonstrate that 
KT recipients with an increasing or stable high BKV load in plasma had a significantly lower 
immune response to the two proteins BKV-LT and -VP1 than with patients that had a 
decreasing viral load or past PVAN (P=0.003 and P=0.001, respectively, Mann Whitney U-
test, two sided). This finding may complement the previously defined threshold plasma viral 
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load of >10'000 DNA copies/ml and thereby enlarge the pool of diagnostic markers to identify 
patients at high risk for PVAN. Hammer et al. recently reported that patients with a plasma 
BKV-DNA load of >250'000 copies/ml and detectable VP1-specific CD8+ T-cell response, 
are at high risk for PVAN development and graft loss. The authors speculate that VP1-
specific CD8+ T-cell in plasma may represent a direct threat for allograft survival (Hammer et 
al. 2006). However, we were able to detect a BKV-specific cellular immune response not only 
to VP1 but also to LT-antigen in patients with a plasma viral load <250'000 copies/ml by 
ESA. Furthermore, we could illustrate that a single measurement of the viral load in plasma 
does not correlate with the cellular immune response to BKV. Viral dynamics rather than a 
snapshot measurement of viral load matters. These findings strongly indicate the need for 
serial PCR in plasma for measurements to guide clinical management of PVAN in KT 
patients (Funk et al. 2006; Lacey 2007). 
A cut-off of 69 SFU per million PBMC for BKV-LT was shown to include most patients 
with a decreasing viral load (P=0.013, Fisher's exact test, two-sided) and could be used as a 
marker to define patients who have regained a protective cellular immune response against 
BKV. BKV-LT antigen is a better discriminator for the group with decreasing viral load than 
BKV-VP1 and the cut-off of 69 SFU per million PBMC may also be useful for monitoring the 
effect of immunosuppressant reduction. However, a well-designed prospective study needs to 
be performed to confirm this cut-off. 
Measuring of the cellular immune response by ESA for identification of a rejection marker 
looks promising. In this context it is tempting to speculate that maybe it is not the cut-off that 
is important for predicting rejection, but rather the dynamics of how quickly the patient is able 
to regain a competent immune system (comparable with BKV load dynamics for risk for 
PVAN). Clearly, this needs further investigation. 
 
 
6.3 Polyomavirus JC and Cross-Recognition 
All study participants (N=42) were also JCV-seropositive. Although BKV and JCV share 
high protein homology for LT (83%) and VP1 (78%), response to BKV-peptides was specific 
and significantly higher than responses to JCV-peptides (P=0.008 and P<0.001, respectively). 
The higher response to BKV-antigen is most likely due to a resent viral exposure. After 9-day 
cultivation the cellular immunity response to BKV-VP1 was significantly higher than 
response to JCV-VP1 (P=0.016), indicating a limited cross-recognition. In contrast, in vitro 
expansion with LT-antigen showed no significant differences after restimulation with either 
BKV- or JCV-LT. It is, therefore, tempting to speculate that immune response to LT-antigen 
is more conserved between BKV and JCV as for VP1. 
We also found cross-recognition with 15aa long LT-antigen single peptides by epitope 
mapping ("Epitope Mapping of BKV-Proteins: LT, VP1 and Agnoprotein") (S. Binggeli, 
current results). The decision to map BKV-LT first and not BKV-VP1 was due to the fact 
that: 1. LT is higher conserved between BKV and JCV, 2. BKV-LT is a better discriminator 
for cellular immune response in KT patients with a decreasing viral load (Binggeli et al. 
2007), and 3. LT-antigen is an early protein and has important functional properties and 
maybe essential in respect to mounting a protective cellular immune response. From an 
evolutionary point of view, it makes sense that a CD8+ T-cell response detects and destroys 
virus infected cells well before they burst and liberate their viral progeny. Thus, BKV-LT 
which is an early protein should be recognized before the late protein VP1 and may play an 
important role in mounting an BKV-specific cellular immune response. 
As the BKV-LT overlapping peptide pool consists of 180 peptides (15aa in length with 
11aa overlaps), it is more time and cost efficient to pool these peptides by 10 peptides per 
pool (subpools) rather than to test each peptide individually. PBMC stimulation with 38 
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different peptide subpools revealed 10 subpools inducing a BKV-LT specific cellular immune 
response (>8 SFU/106 PBMC). The peptide board showed ten single peptides (pp94, pp95, 
pp96, pp164, pp165, pp166, pp230, pp233, pp234) with the potential for inducing a BKV-LT 
specific cellular immune response. Starting with pp94, pp95 and pp96, those single peptides 
showed highest response to pp96 and no response to pp94. Surprisingly, in a later experiment 
pp94 was able to induce an immune response in the same range as for pp95 and pp96. This 
inconsistency could be due to ESA variation or inappropriate addition of pp94. 
Testing for cross-recognition with the homologous JCV single peptides indicated strong 
recognition despite a lower response suggesting a higher specificity for BKV-peptides. The 
question whether these peptides are able to induce an immune response also in CD8+ T-cells 
remains to be open for a future project. Furthermore, tracking the 15aa long peptide to the 
minimal required size of 8aa, 9aa or 10aa is also subject for future analysis. 
The use of BKV-specific epitopes for adoptive T-cell transfer is a promising attempt for 
therapeutical options and more cost and time efficient than using viral lysate or complete 
peptide pools. Specific epitopes may target CD8+ T-cells directly and may also be more 
efficient in T-cell expansion. On the other hand, one depends on the knowledge of 
immunogenic epitopes and certain HLA-types. This can be circumvent by BKV-lysate or -
complete pool which are HLA-independent. BKV-LT epitopes may also serve for KT patient 
monitoring. In addition, these may help to better distinguish those patients with high risk for 
PVAN as proposed by Hammer and colleagues (Hammer et al. 2006). 
As no proven antiviral treatments are available BKV-specific T-cell expansion and 
adoptive T-cell transfer may serve as an alternative to the reduction of immunosuppression in 
KT patients with increasing BKV-replication and increased risk for PVAN. 
 
 
6.4 Antiviral Treatment 
However, new compounds which target BKV are desirable. In contrast to other latent 
viruses like CMV or EBV, there are no proven antiviral drugs available for BKV-treatment. 
Antivirals are especially desirable in the context of multi-organ transplants as reduction of 
immunosuppressive concentration may increase the possibility of rejection in the non-kidney 
allograft or in patients who are not able to control their BKV load after immunosuppressive 
reduction. One natural antiviral compound, IFN-γ, can be produced by different immune cells 
(natural killer cells, CD4+, and CD8+ T-cells) and is secreted upon virus infections (Boehm et 
al. 1997). Abend et al. recently reported the in vitro inhibitory effect of IFN-γ on BKV gene 
expression and replication in primary human renal proximal tubular epithelial cells. 
Furthermore, IFN-γ inhibited the level of the viral progeny >50x (Abend et al. 2007). Whether 
IFN-γ also inhibits BKV-replication in vivo needs more investigation. 
Other observations of anti-BKV properties of cidofovir, leflunomide, quinolone, 
intravenous immunoglobulines, and lactoferrin, have been reported but the reports are 
controversial (Chapter 1.3.3.3) (Josephson 2005; Longhi et al. 2006; Rinaldo et al. 2007). 
More research is necessary to understand the mechanisms by which these compounds act and 
whether there is potential in further developing them to strong and effective antiviral drugs. 
In "Human Polyomavirus type 1 (BK virus) Agnoprotein is abundantly expressed, 
but immunologically ignored" it has been shown by immunostaining of KT biopsies that 
agnoprotein is abundantly expressed but does not induce a humoral or cellular immune 
response  (Leuenberger et al. 2007). Even though agnoprotein is not suitable for immune 
response measurement it could still be an interesting target for antivirals. It is already known 
that BKV-agnoprotein is phosphorylated (Rinaldo et al. 1998) and a recent study analyzed the 
effect of JCV-agnoprotein mutants. JCV-agnoprotein has three potential targets for 
serine/threonine-specific protein kinase C: Ser7, Ser11 and Thr21 (Figure 5.2) (Sariyer et al. 
 DISCUSSION 
_____________________________________________________________________________  
_____________________________________________________________________  
- 118 - 
2006). Conservative substitution of these phosphorylation sites resulted in a viable virus and 
viral particle release from infected cells, but the virus was not able to propagate as the viral 
capsid showed a deficiency in DNA-content. Thus, the viral life cycle ended with an abortive 
replication cycle. Targeting the phosphorylation site of agnoprotein could be an interesting 
approach for new antiviral drugs. The phosphorylation sites are conserved between JCV and 
BKV and we can assume that BKV would also be impaired in propagation if agnoprotein is 
not phosphorylated. To the best of my knowledge there are no published reports concerning 
BKV-agnoprotein and the potential consequences of interfering with its phosphorylation sites. 
Interestingly CMV possesses three tegument proteins which are phosphorylated (pp65, 
pp71, pp150) and it is speculated that inhibiting of protein phosphorylation by leflunomide 
may interfere with tegument assembly (Waldman et al. 1999). Whether leflunomide is also 
able to inhibit BKV-agnoprotein phosphorylation and thus virus propagation needs further 
investigation. 
 
BKV MVLRQLSRQASVKVGKTWTGTKKRAQRIFIFILELLLEFCRGEDSVDGKN 
JCV MVLRQLSRKASVKVSKTWSGTKKRAQRILIFLLEFLLDFCTGEDSVDGKK 
 7 11 21 
 
BKV KS-TTALPAVKDSVKDS---- 
JCV RQRHSGLTEQTYSALPEPKAT 
 
Figure 5.2: Agnoprotein sequence and potential phosphorylation sites (Ser7, Ser11, Thr21). 
Accession number: BKV: P03085, JCV: AAA82098, Clustal W alignment of BKV-Dunlop and 
JCV-MAD1 strains. 
 
BKV-agnoprotein is a very short 66aa long protein and only 14 peptides are necessary to 
cover the whole protein with a peptide library consisting of 15aa in length with 11aa overlaps. 
Therefore, single agnoprotein peptides were used for PBMC stimulation after 9-day 
expansion with complete agnoprotein overlapping peptide pool (OPP). The BKV-specific 
cellular immune response was quantified by ESA. From all 14 peptides, pp8 and pp9 stood 
out, as pp8 is not able to induce any response and response to pp9 was higher (90 SFU/106 
PBMC) than response to the complete pool (70 SFU/106 PBMC). The single peptide pp8 
posseses a long stretch with hydrophobic amino acids which might be unfavorable for binding 
and recognition by MHC and T-cells. Even though pp9 is the neighboring peptide sharing 
11aa, the BKV-specific response of pp9 was very high. This discrepancy between pp8 and 
pp9 immune response could be due to more favorable peptide binding by the groove binding 
sites of MHC-class II due to amino acid sequence or three dimensional structure. 
The association between agnoprotein and the cellular immune response is not understood; 
Further investigation is also needed to understand whether agnoprotein may serve for 
therapeutic purposes. 
 
 
6.5 Limitation of Polyomavirus-Specific Immune Response Measurement 
by ELISpot Assay 
ESA is a very sensitive and convenient assay to measure IFN-γ secretion of PBMCs. 
However, like every method, ESA has its limitations. In the current study "Epitope Mapping 
of BKV-Proteins: LT, VP1 and Agno of a HLA-*A01, HLA-A*03, HLA-B*08, HLA-
B*51, HLA-DR*19, HLA-DR*11 Kidney Patient with Past Polyomavirus Associated 
Nephropathy" ESA was used to measure BKV-specific cellular immune response of either 
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PBMC or BKV-specific expanded CD8+ T-cells for epitope mapping (S. Binggeli, current 
results). 
With ESA the source of IFN-γ secreting cells can not be traced back. As natural killer 
(NK) cells, CD4+ and also CD8+ T-cells secrete IFN-γ upon stimulation, it can not be 
distinguished how much each cell contributes to the IFN-γ response. Thus only the overall 
IFN-γ secretion can be measured. One way to determine the IFN-γ source is cell isolation. 
CD4+ or CD8+ depleted PBMC can be used to estimate how much each cell contributes to 
the IFN-γ response. CD4+ T-cell depletion showed a lower response upon stimulation with 
BKV-LT and -VP1 (51 SFU/106 PBMC, 80 SFU/106 PBMC) than not depleted PBMC (97 
SFU/106 PBMC, 280 SFU/106 PBMC) and CD8+ depleted PBMC (132 SFU/106 PBMC, 520 
SFU/106 PBMC), indicating that the IFN-γ response is derived mostly from CD4+ T-cells. As 
we are using 15aa long peptides for PBMC stimulation we could expect a good response of 
CD4+ T-cells for two reasons: 1. Optimal peptide length for CD4+ T-cell recognition is 
between 13aa and 17aa, and, 2. The peptides are loaded on MHC-class II via the exogenous 
pathway (Rudensky et al. 1991). This argues against an optimal peptide presentation and 
recognition for CD8+ T-cells, as these cells recognize 8-10aa long peptides loaded on MHC-
class I via the endogenous pathway (Rammensee 1995). 
We observed a higher immune response in CD8+ T-cell depleted PBMC (LT: 132 SFU/106 
PBMC, VP1: 520 SFU/106 PBMC) than in the whole PBMC (LT: 97 SFU/106 PBMC, VP1: 
280 SFU/106 PBMC). This discrepancy may be due to the increased concentration of CD4+ 
T-cells after CD8+ T-cell depletion as always the same cell concentration was seeded per well 
for stimulation. In order to distinguish between CD4+ and CD8+ T-cell derived IFN-γ 
secretion, it would be advantagous to use intracellular cytokine staining, or, when using ESA, 
positively selecting T-cells and stimulating them with peptide pulsed mDCs. Both methods 
would exclude a NK-cell derived IFN-γ response. However, the disadvantage of using a 
FACS assay is that a low frequency of IFN-γ secreting T-cells may fall under the detection 
limit (Karlsson et al. 2003; Tassignon et al. 2005). 
Measuring the IFN-γ response of isolated CD8+ T-cells is very difficult for BKV-peptides 
as T-cell frequency is mostly under the detection limit (unpublished data). Therefore, IFN-γ 
detection is only possible with a method sensitive enough to trace IFN-γ at very low levels or 
to expand BKV-specific CD8+ T-cells to reach a higher frequency. For our purposes we 
positively selected CD8+ T-cells out of PBMC and expanded them with viral peptides. To 
establish T-cell expansion in our laboratory, we used PBMC from a HB and CMV-pp65 
peptide library (Appendices 10.3). After three weeks, we were able to expand CMV-pp65 
specific CD8+ T-cells 60x (week 0: 123 SFU/106 PBMC, week 3: 7340 SFU/106 PBMC). Of 
course, this method has to be adapted for KT recipients and as well for BKV-LT, -VP1 and -
agnoprotein. To complete this experiment it could also be established for CD4+ T-cells. 
Whether the cellular immune response of PBMC mirrors the event in the organ remains to 
be investigated. It can be speculated that BKV-specific cellular immune response of PBMC 
reflects the action in the kidney, as the kidney is highly supplied with blood. On the other 
hand, much of the T-cell response may be undetectable in the peripheral blood due to T-cell 
homing. 
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6.6 Concluding Remarks 
In conclusion, it is of high interest to find new biomarkers for monitoring patients after KT 
transplantation in order to prevent PVAN and for better patient management. A stable graft 
function prolongates its survival, and measurement of the BKV-specific cellular immune 
response is one approach for identifying patients at risk for PVAN and supplementing BKV-
load measurement by PCR.  
We could show that a BKV-LT specific cellular immune response above 69 SFU/106 
PBMC correlates with the decline of BK-viral load in plasma and thus with BKV-replication 
control. Furthermore, we found that a FK506 plasma concentration higher 6.65 ng/ml 
significantly increases the risk for BKV-replication. Both cut-offs have to be validated in a 
well designed prospective study. If these cut-offs are confirmed, they may serve as good 
biomarkers for patient monitoring and as guideline for therapeutical decisions. 
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II 
10. APPENDICES 
 
10.1 PEPTIDE LIBRARY BKV DUNLOP STRAIN 
 
10.1.1 Polyomavirus BK-Large T-Antigen (NCBI: P03071) 
89 MDKVLNREESMELMD 134 YSVTFISRHMCAGHN 
90 LNREESMELMDLLGL 135 FISRHMCAGHNIIFF 
91 ESMELMDLLGLERAA 136 HMCAGHNIIFFLTPH 
92 LMDLLGLERAAWGNL 137 GHNIIFFLTPHRHRV 
93 LGLERAAWGNLPLMR 138 IFFLTPHRHRVSAIN 
94 RAAWGNLPLMRKAYL 139 TPHRHRVSAINNFCQ 
95 GNLPLMRKAYLRKCK 140 HRVSAINNFCQKLCT 
96 LMRKAYLRKCKEFHP 141 AINNFCQKLCTFSFL 
97 AYLRKCKEFHPDKGG 142 FCQKLCTFSFLICKG 
98 KCKEFHPDKGGDEDK 143 LCTFSFLICKGVNKE 
99 FHPDKGGDEDKMKRM 144 SFLICKGVNKEYLLY 
100 KGGDEDKMKRMNTLY 145 CKGVNKEYLLYSALT 
101 EDKMKRMNTLYKKME 146 NKEYLLYSALTRDPY 
102 KRMNTLYKKMEQDVK 147 LLYSALTRDPYHTIE 
103 TLYKKMEQDVKVAHQ 148 ALTRDPYHTIEESIQ 
104 KMEQDVKVAHQPDFG 149 DPYHTIEESIQGGLK 
105 DVKVAHQPDFGTWSS 150 TIEESIQGGLKEHDF 
106 AHQPDFGTWSSSEVP 151 SIQGGLKEHDFSPEE 
107 DFGTWSSSEVPTYGT 152 GLKEHDFSPEEPEET 
108 WSSSEVPTYGTEEWE 153 HDFSPEEPEETKQVS 
109 EVPTYGTEEWESWWS 154 PEEPEETKQVSWKLI 
110 YGTEEWESWWSSFNE 155 EETKQVSWKLITEYA 
111 EWESWWSSFNEKWDE 156 VSWKLITEYAVETK 
112 WWSSFNEKWDEDLFC 157 KLITEYAVETKCEDV 
113 FNEKWDEDLFCHEDM 158 EYAVETKCEDVFLLL 
114 WDEDLFCHEDMFASD 159 ETKCEDVFLLLGMYL 
115 LFCHEDMFASDEEAT 160 EDVFLLLGMYLEFQY 
116 EDMFASDEEATADSQ 161 LLLGMYLEFQYNVEE 
117 ASDEEATADSQHSTP 162 MYLEFQYNVEECKKC 
118 EATADSQHSTPPKKK 163 FQYNVEECKKCQKKD 
119 DSQHSTPPKKKRKVE 164 VEECKKCQKKDQPYH 
120 STPPKKKRKVEDPKD 165 KKCQKKDQPYHFKYH 
121 KKKRKVEDPKDFPSD 166 KKDQPYHFKYHEKHF 
122 KVEDPKDFPSDLHQF 167 PYHFKYHEKHFANAI 
123 PKDFPSDLHQFLSQA 168 KYHEKHFANAIIFAE 
124 PSDLHQFLSQAVFSN 169 KHFANAIIFAESKNQ 
125 HQFLSQAVFSNRTLA 170 NAIIFAESKNQKSIC 
126 SQAVFSNRTLACFAV 171 FAESKNQKSICQQAV 
127 FSNRTLACFAVYTTK 172 KNQKSICQQAVDTVL 
128 TLACFAVYTTKEKAQ 173 SICQQAVDTVLAKKR 
129 FAVYTTKEKAQILYK 174 AVDTVLAKKRVDTL 
130 TTKEKAQILYKKLME 175 TVLAKKRVDTLHMTR 
131 KAQILYKKLMEKYSV 176 KKRVDTLHMTREEML 
132 LYKKLMEKYSVTFIS 177 DTLHMTREEMLTERF 
133 LMEKYSVTFISRHMC 178 MTREEMLTERFNHIL 
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...Continued 
 
Polyomavirus BK-Large T-Antigen (NCBI: P03071) 
179 EMLTERFNHILDKMD 224 ARFVRQIDFRPKIYL 
180 ERFNHILDKMDLIFG 225 RQIDFRPKIYLRKSL 
181 HILDKMDLIFGAHGN 226 FRPKIYLRKSLQNSE 
182 KMDLIFGAHGNAVLE 227 IYLRKSLQNSEFLLE 
183 IFGAHGNAVLEQYMA 228 KSLQNSEFLLEKRIL 
184 HGNAVLEQYMAGVAW 229 NSEFLLEKRILQSGM 
185 VLEQYMAGVAWLHCL 230 LLEKRILQSGMTLLL 
186 YMAGVAWLHCLLPKM 231 RILQSGMTLLLLLIW 
187 VAWLHCLLPKMDSVI 232 SGMTLLLLLIWFRPV 
188 HCLLPKMDSVIFDFL 233 LLLLLIWFRPVADFA 
189 PKMDSVIFDFLHCIV 234 LIWFRPVADFATDIQ 
190 SVIFDFLHCIVFNVP 235 RPVADFATDIQSRIV 
191 DFLHCIVFNVPKRRY 236 DFATDIQSRIVEWKE 
192 CIVFNVPKRRYWLFK 237 DIQSRIVEWKERLDS 
193 NVPKRRYWLFKGPID 238 RIVEWKERLDSEISM 
194 RRYWLFKGPIDSGKT 239 WKERLDSEISMYTFS 
195 LFKGPIDSGKTTLAA 240 LDSEISMYTFSRMKY 
196 PIDSGKTTLAAGLLD 241 ISMYTFSRMKYNICM 
197 GKTTLAAGLLDLCGG 242 TFSRMKYNICMGKCI 
198 LAAGLLDLCGGKALN 243 MKYNICMGKCILDIT 
199 LLDLCGGKALNVNLP 244 ICMGKCILDITREED 
200 CGGKALNVNLPMERL 245 KCILDITREEDSETE 
201 ALNVNLPMERLTFEL 246 DITREEDSETEDSGH 
202 NLPMERLTFELGVAI 247 EEDSETEDSGHGSST 
203 ERLTFELGVAIDQYM 248 ETEDSGHGSSTESQS 
204 FELGVAIDQYMVVFE 249 SGHGSSTESQSQCSS 
205 VAIDQYMVVFEDVKG 250 SSTESQSQCSSQVSD 
206 YMVVFEDVKGTGAE 251 SQSQCSSQVSDTSAP 
207 VFEDVKGTGAESKDL 252 CSSQVSDTSAPAEDS 
208 VKGTGAESKDLPSGH 253 VSDTSAPAEDSQRSD 
209 GAESKDLPSGHGINN 254 SAPAEDSQRSDPHSQ 
210 KDLPSGHGINNLDSL 255 EDSQRSDPHSQELHL 
211 SGHGINNLDSLRDYL 256 RSDPHSQELHLCKGF 
212 INNLDSLRDYLDGSV 257 HSQELHLCKGFQCFK 
213 DSLRDYLDGSVKVNL 258 LHLCKGFQCFKRPKT 
214 DYLDGSVKVNLEKKH 259 KGFQCFKRPKTPPPK 
215 GSVKVNLEKKHLNKR 260 DTSAPAEDSQRSDPH 
216 VNLEKKHLNKRTQIF 261 APAEDSQRSDPHSQE 
217 KKHLNKRTQIFPPGL 262 EDSQRSDPHSQELHL 
218 NKRTQIFPPGLVTMN 263 RSDPHSQELHLCKG 
219 IFPPGLVTMNEYPV 264 DPHSQELHLCKGFQC 
220 PGLVTMNEYPVPKTL 265 SQELHLCKGFQCFKR 
221 TMNEYPVPKTLQARF 266 LHLCKGFQCFKRPKT 
222 YPVPKTLQARFVRQI 267 CKGFQCFKRPKTPPP 
223 KTLQARFVRQIDFRP 268 FQCFKRPKTPPPK 
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10.1.2 Polyomavirus BK-VP1 (NCBI: P03088) 
1 MAPTKRKGECPGAAP 45 TITPKNPTAQSQVMN 
2 KRKGECPGAAPKKPK 46 KNPTAQSQVMNTDHK 
3 ECPGAAPKKPKEPVQ 47 AQSQVMNTDHKAYLD 
4 AAPKKPKEPVQVPKL 48 VMNTDHKAYLDKNNA 
5 KPKEPVQVPKLLIKG 49 DHKAYLDKNNAYPVE 
6 PVQVPKLLIKGGVEV 50 YLDKNNAYPVECWVP 
7 PKLLIKGGVEVLEVK 51 NNAYPVECWVPDPSR 
8 IKGGVEVLEVKTGVD 52 PVECWVPDPSRNENA 
9 VEVLEVKTGVDAITE 53 WVPDPSRNENARYFG 
10 EVKTGVDAITEVECF 54 PSRNENARYFGTFTG 
11 GVDAITEVECFLNPE 55 ENARYFGTFTGGENV 
12 ITEVECFLNPEMGDP 56 YFGTFTGGENVPPVL 
13 ECFLNPEMGDPDENL 57 FTGGENVPPVLHVTN 
14 NPEMGDPDENLRGFS 58 ENVPPVLHVTNTATT 
15 GDPDENLRGFSLKLS 59 PVLHVTNTATTVLLD 
16 ENLRGFSLKLSAEND 60 VTNTATTVLLDEQGV 
17 GFSLKLSAENDFSSD 61 ATTVLLDEQGVGPLC 
18 KLSAENDFSSDSPER 62 LLDEQGVGPLCKADS 
19 ENDFSSDSPERKMLP 63 GVGPLCKADSLYVS 
20 SSDSPERKMLPCYST 64 PLCKADSLYVSAADI 
21 PERKMLPCYSTARIP 65 ADSLYVSAADICGLF 
22 MLPCYSTARIPLPNL 66 YVSAADICGLFTNSS 
23 YSTARIPLPNLNEDL 67 ADICGLFTNSSGTQQ 
24 RIPLPNLNEDLTCGN 68 GLFTNSSGTQQWRGL 
25 PNLNEDLTCGNLLMW 69 NSSGTQQWRGLARYF 
26 EDLTCGNLLMWEAVT 70 TQQWRGLARYFKIRL 
27 CGNLLMWEAVTVQTE 71 RGLARYFKIRLRKRS 
28 LMWEAVTVQTEVIGI 72 RYFKIRLRKRSVKNP 
29 AVTVQTEVIGITSML 73 IRLRKRSVKNPYPIS 
30 TEVIGITSMLNLHA 74 KRSVKNPYPISFLLS 
31 IGITSMLNLHAGSQK 75 KNPYPISFLLSDLIN 
32 SMLNLHAGSQKVHEH 76 PISFLLSDLINRRTQ 
33 LHAGSQKVHEHGGGK 77 LLSDLINRRTQRVDG 
34 SQKVHEHGGGKPIQG 78 LINRRTQRVDGQPMY 
35 HEHGGGKPIQGSNFH 79 RTQRVDGQPMYGMES 
36 GGKPIQGSNFHFFAV 80 VDGQPMYGMESQVEE 
37 IQGSNFHFFAVGGEP 81 PMYGMESQVEEVRVF 
38 NFHFFAVGGEPLEMQ 82 MESQVEEVRVFDGTE 
39 FAVGGEPLEMQGVLM 83 VEEVRVFDGTERLPG 
40 GEPLEMQGVLMNYRS 84 RVFDGTERLPGDPDM 
41 EMQGVLMNYRSKYPD 85 GTERLPGDPDMIRYI 
42 VLMNYRSKYPDGTIT 86 LPGDPDMIRYIDKQG 
43 YRSKYPDGTITPKNP 87 PDMIRYIDKQGQLQT 
44 YPDGTITPKNPTAQS 88 RYIDKQGQLQTKML 
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10.1.3 Polyomavirus BK-Agnoprotein (NCBI: P03085) 
1 MVLRQLSRQASVKVG 
2 LSRQASVKVGKTWT 
3 ASVKVGKTWTGTKK 
4 KVGKTWTGTKKRAQR 
5 TWTGTKKRAQRIFIF 
6 TKKRAQRIFIFILEL 
7 AQRIFIFILELLLEF 
8 FIFILELLLEFCRGE 
9 LELLLEFCRGEDSVD 
10 LEFCRGEDSVDGKNK 
11 RGEDSVDGKNKSTTA 
12 SVDGKNKSTTALPAV 
13 KNKSTTALPAVKDSV 
14 TTALPAVKDSVKDS 
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VI 
10.2 PEPTIDE LIBRARY JCV MAD1 STRAIN 
 
10.2.1 Polyomavirus JC-Large T-Antigen (NCBI: AAA82102) 
240 MDKVLNREESMELMD 283 YKKLMEKYSVTFISR 
241 LNREESMELMDLLGL 284 MEKYSVTFISRHGFG 
242 ESMELMDLLGLDRSA 285 SVTFISRHGFGGHNI 
243 LMDLLGLDRSAWGNI 286 ISRHGFGGHNILFFL 
244 LGLDRSAWGNIPVMR 287 GFGGHNILFFLTPHR 
245 RSAWGNIPVMRKAYL 288 HNILFFLTPHRHRVS 
246 GNIPVMRKAYLKKCK 289 FFLTPHRHRVSAINN 
247 VMRKAYLKKCKELHP 290 PHRHRVSAINNYCQK 
248 AYLKKCKELHPDKGG 291 RVSAINNYCQKLCTF 
249 KCKELHPDKGGDEDK 292 INNYCQKLCTFSFLI 
250 LHPDKGGDEDKMKRM 293 CQKLCTFSFLICKGV 
251 KGGDEDKMKRMNFLY 294 CTFSFLICKGVNKEY 
252 EDKMKRMNFLYKKME 295 FLICKGVNKEYLFYS 
253 KRMNFLYKKMEQGVK 296 KGVNKEYLFYSALCR 
254 FLYKKMEQGVKVAHQ 297 KEYLFYSALCRQPYA 
255 KMEQGVKVAHQPDFG 298 FYSALCRQPYAVVEE 
256 GVKVAHQPDFGTWNS 299 LCRQPYAVVEESIQG 
257 AHQPDFGTWNSSEVP 300 PYAVVEESIQGGLKE 
258 DFGTWNSSEVPTYGT 301 VEESIQGGLKEHDFN 
259 WNSSEVPTYGTDEWE 302 IQGGLKEHDFNPEEP 
260 EVPTYGTDEWESWWN 303 LKEHDFNPEEPEETK 
261 YGTDEWESWWNTFNE 304 DFNPEEPEETKQVSW 
262 EWESWWNTFNEKWDE 305 EEPEETKQVSWKLVT 
263 WWNTFNEKWDEDLFC 306 ETKQVSWKLVTQYAL 
264 FNEKWDEDLFCHEEM 307 VSWKLVTQYALETKC 
265 WDEDLFCHEEMFASD 308 LVTQYALETKCEDVF 
266 LFCHEEMFASDDENT 309 YALETKCEDVFLLMG 
267 EEMFASDDENTGSQH 310 TKCEDVFLLMGMYLD 
268 ASDDENTGSQHSTPP 311 DVFLLMGMYLDFQEN 
269 ENTGSQHSTPPKKKK 312 LMGMYLDFQENPQQC 
270 SQHSTPPKKKKKVED 313 YLDFQENPQQCKKCE 
271 TPPKKKKKVEDPKDF 314 ENPQQCKKCEKKDQ 
272 KKKKVEDPKDFPVDL 315 CKKCEKKDQPNHF 
273 VEDPKDFPVDLHAFL 316 KCEKKDQPNHFNHHE 
274 KDFPVDLHAFLSQAV 317 KDQPNHFNHHEKHYY 
275 VDLHAFLSQAVFSNR 318 NHFNHHEKHYYNAQI 
276 AFLSQAVFSNRTVAS 319 HHEKHYYNAQIFADS 
277 AVFSNRTVASFAVY 320 HYYNAQIFADSKNQK 
278 SNRTVASFAVYTTKE 321 AQIFADSKNQKSICQ 
279 VASFAVYTTKEKAQI 322 ADSKNQKSICQQAVD 
280 AVYTTKEKAQILYKK 323 NQKSICQQAVDTVAA 
281 TKEKAQILYKKLMEK 324 ICQQAVDTVAAKQRV 
282 AQILYKKLMEKYSVT 325 AVDTVAAKQRVDSIH 
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VII 
...Continued 
 
Polyomavirus JC-Large T-Antigen (NCBI: AAA82102) 
326 VAAKQRVDSIHMTRE 369 KRTQVFPPGIVTMNE 
327 RVDSIHMTREEMLV 370 VFPPGIVTMNEYSVP 
328 SIHMTREEMLVERFN 371 GIVTMNEYSVPRTLQ 
329 TREEMLVERFNFLLD 372 MNEYSVPRTLQARFV 
330 MLVERFNFLLDKMDL 373 SVPRTLQARFVRQID 
331 RFNFLLDKMDLIFGA 374 TLQARFVRQIDFRPK 
332 LLDKMDLIFGAHGNA 375 RFVRQIDFRPKAYLR 
333 MDLIFGAHGNAVLEQ 376 IDFRPKAYLRKSLS 
334 FGAHGNAVLEQYMAG 377 RPKAYLRKSLSCSEY 
335 GNAVLEQYMAGVAWI 378 YLRKSLSCSEYLLEK 
336 LEQYMAGVAWIHCLL 379 SLSCSEYLLEKRILQ 
337 MAGVAWIHCLLPQMD 380 SEYLLEKRILQSGMT 
338 AWIHCLLPQMDTVIY 381 LEKRILQSGMTLLLL 
339 CLLPQMDTVIYDFLK 382 ILQSGMTLLLLLIWF 
340 MDTVIYDFLKCIVL 383 GMTLLLLLIWFRPVA 
341 VIYDFLKCIVLNIPK 384 LLLLIWFRPVADFAA 
342 FLKCIVLNIPKKRYW 385 IWFRPVADFAAAIHE 
343 IVLNIPKKRYWLFKG 386 PVADFAAAIHERIVQ 
344 IPKKRYWLFKGPIDS 387 FAAAIHERIVQWKER 
345 RYWLFKGPIDSGKTT 388 IHERIVQWKERLDLE 
346 FKGPIDSGKTTLAAA 389 IVQWKERLDLEISMY 
347 IDSGKTTLAAALLDL 390 KERLDLEISMYTFST 
348 KTTLAAALLDLCGGK 391 DLEISMYTFSTMKAN 
349 AAALLDLCGGKSLNV 392 SMYTFSTMKANVGMG 
350 LDLCGGKSLNVNMPL 393 FSTMKANVGMGRPIL 
351 GGKSLNVNMPLERLN 394 KANVGMGRPILDFPR 
352 LNVNMPLERLNFELG 395 GMGRPILDFPREEDS 
353 MPLERLNFELGVGID 396 PILDFPREEDSEAED 
354 RLNFELGVGIDQFMV 397 FPREEDSEAEDSGHG 
355 ELGVGIDQFMVVFED 398 EDSEAEDSGHGSSTE 
356 GIDQFMVVFEDVKGT 399 AEDSGHGSSTESQSQ 
357 FMVVFEDVKGTGAES 400 GHGSSTESQSQCFSQ 
358 FEDVKGTGAESRDLP 401 STESQSQCFSQVSEA 
359 KGTGAESRDLPSGHG 402 SQCFSQVSEASGAD 
360 AESRDLPSGHGISNL 403 FSQVSEASGADTQEN 
361 DLPSGHGISNLDCLR 404 SEASGADTQENCTFH 
362 GHGISNLDCLRDYLD 405 GADTQENCTFHICKG 
363 SNLDCLRDYLDGSVK 406 ENCTFHICKGFQCF 
364 CLRDYLDGSVKVNLE 407 TFHICKGFQCFKKPK 
365 YLDGSVKVNLERKHQ 408 CKGFQCFKKPKTPPP 
366 SVKVNLERKHQNKRT 409 CFKKPKTPPPK 
367 NLERKHQNKRTQVFP     
368 KHQNKRTQVFPPGIV     
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VIII 
10.2.2 Polyomavirus JC-VP1 (NCBI: AAA82101) 
1 MAPTKRKGERKDPVQ 45 VQSQVMNTEHKAYLD 
2 KRKGERKDPVQVPKL 46 VMNTEHKAYLDKNKA 
3 ERKDPVQVPKLLIRG 47 EHKAYLDKNKAYPVE 
4 PVQVPKLLIRGGVEV 48 YLDKNKAYPVECWVP 
5 PKLLIRGGVEVLEVK 49 NKAYPVECWVPDPTR 
6 IRGGVEVLEVKTGVD 50 PVECWVPDPTRNENT 
7 VEVLEVKTGVDSITE 51 WVPDPTRNENTRYFG 
8 EVKTGVDSITEVECF 52 PTRNENTRYFGTLTG 
9 GVDSITEVECFLTPE 53 ENTRYFGTLTGGENV 
10 ITEVECFLTPEMGDP 54 YFGTLTGGENVPPVL 
11 ECFLTPEMGDPDEHL 55 LTGGENVPPVLHITN 
12 TPEMGDPDEHLRGFS 56 ENVPPVLHITNTATT 
13 GDPDEHLRGFSKSIS 57 PVLHITNTATTVLLD 
14 EHLRGFSKSISISDT 58 ITNTATTVLLDEFGV 
15 GFSKSISISDTFESD 59 ATTVLLDEFGVGPLC 
16 SISISDTFESDSPNR 60 LLDEFGVGPLCKGDN 
17 SDTFESDSPNRDMLP 61 FGVGPLCKGDNLYLS 
18 ESDSPNRDMLPCYSV 62 PLCKGDNLYLSAVDV 
19 PNRDMLPCYSVARIP 63 GDNLYLSAVDVCGMF 
20 MLPCYSVARIPLPNL 64 YLSAVDVCGMFTNRS 
21 YSVARIPLPNLNEDL 65 VDVCGMFTNRSGSQQ 
22 RIPLPNLNEDLTCGN 66 GMFTNRSGSQQWRGL 
23 PNLNEDLTCGNILMW 67 NRSGSQQWRGLSRYF 
24 EDLTCGNILMWEAVT 68 SQQWRGLSRYFKVQL 
25 CGNILMWEAVTLKTE 69 RGLSRYFKVQLRKRR 
26 LMWEAVTLKTEVIGV 70 RYFKVQLRKRRVKNP 
27 AVTLKTEVIGVTSLM 71 VQLRKRRVKNPYPIS 
28 KTEVIGVTSLMNVHS 72 KRRVKNPYPISFLLT 
29 IGVTSLMNVHSNGQA 73 KNPYPISFLLTDLIN 
30 SLMNVHSNGQATHDN 74 PISFLLTDLINRRTP 
31 VHSNGQATHDNGAGK 75 LLTDLINRRTPRVDG 
32 GQATHDNGAGKPVQG 76 LINRRTPRVDGQPMY 
33 HDNGAGKPVQGTSFH 77 RTPRVDGQPMYGMDA 
34 AGKPVQGTSFHFFSV 78 VDGQPMYGMDAQVEE 
35 VQGTSFHFFSVGGEA 79 PMYGMDAQVEEVRVF 
36 SFHFFSVGGEALELQ 80 MDAQVEEVRVFEGTE 
37 FSVGGEALELQGVLF 81 VEEVRVFEGTEELPG 
38 GEALELQGVLFNYRT 82 RVFEGTEELPGDPDM 
39 ELQGVLFNYRTKYPD 83 GTEELPGDPDMMRYV 
40 VLFNYRTKYPDGTIF 84 LPGDPDMMRYVDKYG 
41 YRTKYPDGTIFPKNA 85 PDMMRYVDKYGQLQT 
42 YPDGTIFPKNATVQS 86 RYVDKYGQLQTKML 
43 TIFPKNATVQSQVMN     
44 KNATVQSQVMNTEHK     
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IX 
10.2.3 Polyomavirus JC-Agnoprotein (NCBI: AAA82098) 
1 MVLRQLSRKASVKVS 
2 LSRKASVKVSKTWS 
3 KASVKVSKTWSGTKK 
4 KVSKTWSGTKKRAQR 
5 TWSGTKKRAQRILIF 
6 TKKRAQRILIFLLEF 
7 AQRILIFLLEFLLDF 
8 LIFLLEFLLDFCTGE 
9 LEFLLDFCTGEDSVD 
10 LDFCTGEDSVDGKKR 
11 TGEDSVDGKKRQRHS 
12 SVDGKKRQRHSGLTE 
13 KKRQRHSGLTEQTYS 
14 RHSGLTEQTYSALPE 
15 LTEQTYSALPEPKAT 
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X 
10.3 PEPTIDE LIBRARY CMV AD169 STRAIN 
 
10.3.1 CMV-pp65 (NCBI: DAA00112) 
1 MESRGRRCPEMISVL 47 AFVFPTKDVALRHVV 93 FTSQYRIQGKLEYRH 
2 GRRCPEMISVLGPIS 48 PTKDVALRHVVCAHE 94 YRIQGKLEYRHTWDR 
3 PEMISVLGPISGHVL 49 VALRHVVCAHELVCS 95 GKLEYRHTWDRHDEG 
4 SVLGPISGHVLKAVF 50 HVVCAHELVCSMENT 96 YRHTWDRHDEGAAQG 
5 PISGHVLKAVFSRGD 51 AHELVCSMENTRATK 97 WDRHDEGAAQGDDDV 
6 HVLKAVFSRGDTPVL 52 VCSMENTRATKMQVI 98 DEGAAQGDDDVWTSG 
7 AVFSRGDTPVLPHET 53 ENTRATKMQVIGDQY 99 AQGDDDVWTSGSDSD 
8 RGDTPVLPHETRLLQ 54 ATKMQVIGDQYVKVY 100 DDVWTSGSDSDEELV 
9 PVLPHETRLLQTGIH 55 VIGDQYVKVYLESF 101 TSGSDSDEELVTTER 
10 HETRLLQTGIHVRVS 56 DQYVKVYLESFCEDV 102 DSDEELVTTERKTPR 
11 LLQTGIHVRVSQPSL 57 KVYLESFCEDVPSGK 103 ELVTTERKTPRVTGG 
12 GIHVRVSQPSLILVS 58 ESFCEDVPSGKLFMH 104 TERKTPRVTGGGAMA 
13 RVSQPSLILVSQYTP 59 EDVPSGKLFMHVTLG 105 TPRVTGGGAMAGAST 
14 PSLILVSQYTPDSTP 60 SGKLFMHVTLGSDVE 106 TGGGAMAGASTSAGR 
15 LVSQYTPDSTPCHRG 61 FMHVTLGSDVEEDLT 107 AMAGASTSAGRKRKS 
16 YTPDSTPCHRGDNQL 62 TLGSDVEEDLTMTRN 108 ASTSAGRKRKSASSA 
17 STPCHRGDNQLQVQH 63 DVEEDLTMTRNPQPF 109 AGRKRKSASSATACT 
18 HRGDNQLQVQHTYFT 64 DLTMTRNPQPFMRPH 110 RKSASSATACTSGVM 
19 NQLQVQHTYFTGSEV 65 TRNPQPFMRPHERNG 111 SSATACTSGVMTRGR 
20 VQHTYFTGSEVENVS 66 PFMRPHERNGFTVL 112 ACTSGVMTRGRLKAE 
21 YFTGSEVENVSVNVH 67 RPHERNGFTVLCPKN 113 GVMTRGRLKAESTVA 
22 SEVENVSVNVHNPTG 68 RNGFTVLCPKNMIIK 114 RGRLKAESTVAPEED 
23 NVSVNVHNPTGRSIC 69 TVLCPKNMIIKPGKI 115 KAESTVAPEEDTDED 
24 NVHNPTGRSICPSQE 70 PKNMIIKPGKISHIM 116 TVAPEEDTDEDSDNE 
25 PTGRSICPSQEPMSI 71 IIKPGKISHIMLDVA 117 EEDTDEDSDNEIHNP 
26 SICPSQEPMSIYVYA 72 GKISHIMLDVAFTSH 118 DEDSDNEIHNPAVFT 
27 SQEPMSIYVYALPLK 73 HIMLDVAFTSHEHFG 119 DNEIHNPAVFTWPPW 
28 MSIYVYALPLKMLNI 74 DVAFTSHEHFGLLCP 120 HNPAVFTWPPWQAGI 
29 VYALPLKMLNIPSIN 75 TSHEHFGLLCPKSIP 121 VFTWPPWQAGILARN 
30 PLKMLNIPSINVHHY 76 HFGLLCPKSIPGLSI 122 PPWQAGILARNLVPM 
31 LNIPSINVHHYPSAA 77 LCPKSIPGLSISGNL 123 AGILARNLVPMVATV 
32 SINVHHYPSAAERKH 78 SIPGLSISGNLLMNG 124 ARNLVPMVATVQGQN 
33 HHYPSAAERKHRHLP 79 LSISGNLLMNGQQIF 125 VPMVATVQGQNLKYQ 
34 SAAERKHRHLPVADA 80 GNLLMNGQQIFLEVQ 126 ATVQGQNLKYQEFFW 
35 RKHRHLPVADAVIHA 81 MNGQQIFLEVQAIRE 127 GQNLKYQEFFWDAND 
36 HLPVADAVIHASGKQ 82 IFLEVQAIRETVEL 128 KYQEFFWDANDIYRI 
37 ADAVIHASGKQMWQA 83 EVQAIRETVELRQYD 129 FFWDANDIYRIFAEL 
38 IHASGKQMWQARLTV 84 IRETVELRQYDPVAA 130 ANDIYRIFAELEGVW 
39 GKQMWQARLTVSGLA 85 VELRQYDPVAALFFF 131 YRIFAELEGVWQPAA 
40 WQARLTVSGLAWTRQ 86 YDPVAALFFFDIDL 132 AELEGVWQPAAQPKR 
41 LTVSGLAWTRQQNQW 87 VAALFFFDIDLLLQR 133 GVWQPAAQPKRRRHR 
42 GLAWTRQQNQWKEPD 88 FFFDIDLLLQRGPQY 134 PAAQPKRRRHRQDAL 
43 TRQQNQWKEPDVYYT 89 IDLLLQRGPQYSEHP 135 PKRRRHRQDALPGPC 
44 NQWKEPDVYYTSAFV 90 LQRGPQYSEHPTFTS 136 RHRQDALPGPCIAST 
45 EPDVYYTSAFVFPTK 91 PQYSEHPTFTSQYRI 137 DALPGPCIASTPKKH 
46 YYTSAFVFPTKDVAL 92 EHPTFTSQYRIQGKL 138 GPCIASTPKKHRG 
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XI 
10.4 USEFUL LINKS 
 
10.4.1 Swisstransplant 
www.swisstransplant.org 
 
10.4.2 National Center for Biotechnology Information (NCBI) 
www.ncbi.nlm.nih.gov 
 
10.4.3 Database for Peptide Motifs 
www.syfpeithi.de 
www-bimas.cit.nih.gov/molbio/hla_bind 
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XII 
10.5 POSTER PRESENTATIONS 
10.5.1 8th Annual Meeting of ESCV (European Society for Clinical Virology), 
Geneva, Switzerland 
APPENDICES 
_____________________________________________________________________________  
_____________________________________________________________________  
XIII 
10.5.2 Annual Congress SGAI-SSAI (Swiss Society for Allergology and Immunology), 
Basel, Switzerland 
